

Fragment-Based Lead Generation of 5-Phenyl-1*H*-pyrazole-3-carboxamide Derivatives as Leads for Potent Factor X_{II}a Inhibitors

Qunchao Wei ^{1,2}, Zhichao Zheng ², Shijun Zhang ², Xuemin Zheng ², Fancui Meng ², Jing Yuan ², Yongnan Xu ^{1,*} and Changjiang Huang ^{2,*}

¹ School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China; wei_qunchao@126.com

² Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China; zhengzc@tjipr.com (Z.Z.); zhangsj@tjipr.com (S.Z.); zhengxm@tjipr.com (X.Z.); mengfc@tjipr.com (F.M.); yuanj@tjipr.com (J.Y.)

* Correspondence: ynxu@syphu.edu.cn or ynanxu@hotmail.com (Y.X.); huangcj@tjipr.com (C.H.); Tel.: +86-24-4352-0248 (Y.X.); +86-22-2300-6833 (C.H.)

Academic Editor: Johannes Reynisson

Received: 23 July 2018; Accepted: 9 August 2018; Published: 10 August 2018

Abstract: FXIa is suggested as a major target for anticoagulant drug discovery because of reduced risk of bleeding. In this paper, we defined 5-phenyl-1*H*-pyrazole-3-carboxylic acid derivatives as privileged fragments for FXIa inhibitors' lead discovery. After replacing the (*E*)-3-(5-chloro-2-(1*H*-tetrazol-1-yl)phenyl)acrylamide moiety in compound **3** with 5-(3-chlorophenyl)-1*H*-pyrazole-3-carboxamide, we traveled from FXIa inhibitor **3** to a scaffold that fused the privileged fragments into a pharmacophore for FXIa inhibitors. Subsequently, we synthesized and assessed the FXIa inhibitory potency of a series of 5-phenyl-1*H*-pyrazole-3-carboxamide derivatives with different P1, P1' and P2' moiety. Finally, the SAR of them was systematically investigated to afford the lead compound **7a** (FXIa *K_i* = 90.37 nM, 1.5× aPTT in rabbit plasma = 43.33 μM) which exhibited good in vitro inhibitory potency against FXIa and excellent in vitro coagulation activities. Furthermore, the binding mode of **7a** with FXIa was studied and the results suggest that the 2-methylcyclopropanecarboxamide group of **7a** makes 2 direct hydrogen bonds with Tyr58B and Thr35 in the FXIa backbone, making **7a** binds to FXIa in a highly efficient manner.

Keywords: thrombosis; coagulation factors; FXIa inhibitors; docking stimulation; computer-aided drug design

1. Introduction

Cardiovascular (CV) disease continues to be the leading cause of death worldwide [1]. Thrombosis is the common underlying pathology of cardiovascular diseases and anticoagulants are the mainstay to prevent and/or treat thrombosis [2]. In clinical use, anticoagulants include antithrombin activators (heparins including unfractionated heparin, low molecular weight heparins and fondaparinux), vitamin K antagonists (coumarins such as warfarin), direct inhibitors of thrombin (hirudins, argatroban and dabigatran etexilate) and oral direct FXa inhibitors (rivaroxaban, apixaban, edoxaban and betrixaban) [3]. Although these agents possess high efficacy and relatively low cost to benefit ratio, they still remain be associated with the life-threatening side effect of internal bleeding [4,5]. Therefore, despite the progresses made in past few years, there is

also an urgent clinical need for developing new anticoagulants to prevent and/or treat thromboembolic diseases without the risk of bleeding or with low bleeding risk.

Generally, it is known from coagulation cascade that proteins in the intrinsic pathway are more important for the amplification phase of coagulation, whereas those belonging to the extrinsic and common coagulation pathways are more involved in the initiation and propagation phases. Current anticoagulants used for treating thrombosis mainly target two key serine proteases, thrombin and factor Xa (FXa), and they both belong to the common pathway of the coagulation cascade. Meanwhile, it has been postulated that selective inhibition of intrinsic coagulation factors could provide antithrombotic benefits with low bleeding risk because this will keep the other pathways of coagulation intact for hemostasis [6–8]. It's shown by epidemiological and clinical studies that the inhibition of Factor XIa (FXIa) which belongs to the intrinsic pathway of the coagulation cascade has emerged as an excellent way to achieve anticoagulation without significant effects on hemostasis [9]. Human FXI deficiency (hemophilia C) was first described as a mild to moderate bleeding disorder [10]. However, these affected patients rarely suffer from spontaneous bleeding episodes. Furthermore, epidemiologic studies showed an increased risk of thrombosis in subjects with elevated FXI levels and some protection from thrombosis in subjects with reduced FXI levels [11,12]. Furthermore, the open-label, parallel-group Phase II study (NCT01713361) showed that reducing FXI levels specifically by an antisense oligonucleotide in patients undergoing elective knee arthroplasty was an effective method for postoperative venous thromboembolism prevention and appeared to be safe with respect to the risk of bleeding [13]. In addition, the Phase I study (NCT03197779) showed that the small molecule FXIa inhibitor BMS-962212 had good enough tolerability, pharmacokinetics and pharmacodynamics properties suitable for investigational use as an acute antithrombotic agent in Japanese or non-Japanese subjects [14,15]. In summary, FXIa is suggested as a major target for anticoagulant drug discovery because of reduced risk of bleeding [7].

In recent years, lots of small molecule FXIa inhibitors were reported, including compounds 1–6 [16–21] and BMS-962212 [15] (Figure 1). Nevertheless, small molecule FXIa inhibitors' research remained in clinical phase. Further development of novel small molecule FXIa inhibitors and investigation of their Structure-Activity Relationships (SAR) are required. It was reported compound 3 exhibited good FXIa affinity activities (FXIa K_i = 2nM) but short $t_{1/2}$ lives and other drawbacks.




Figure 1. The representative FXIa inhibitors.

As shown in Figure 2a, the structure 3 binds to FXIa in S1-S1'-S2' mode. P1, P1 prime (P1') and P2 prime (P2') moieties of compound 3 occupy the S1, S1' and S2' pocket of FXIa (Figure 2a). The carbonyl groups of the cinnamide linker in the P1 and P1' moieties are well positioned within the oxyanion hole by forming key hydrogen bonds with Ser195 residue (Figure 2b); In addition, the amide NH functional group forms a water mediated hydrogen bond with Leu41 [18]. It's obvious that the mentioned two linkers are crucial to ligands' binding mode and it's necessary to retain the two linkers in the structure optimization.




Figure 2. (a) Crystal structure of compound 3 in complex with FXIa (Hydrophobicity surface, PDB ID 5E2O); (b) Crystal structure of compound 3 in complex with FXIa (Binding mode) [18].

It's summarized that some known FXIa inhibitors such as compound 3, 4, 6 (Figure 1) were consisted of 4 parts—P1, P1 prime (P1'), P2 prime (P2') moieties and scaffold. It's the molecule which was developed as a FXIa inhibitor and each part of the molecule was necessary but might be not crucial for the overall activity generally. Therefore, it's reasonable to choose an useful building block as part of FXIa inhibitors. Meanwhile, it is shown clearly that compounds 1–2 and 8–10 (Figure 3) were all based on the 5-phenyl-1*H*-pyrazole-3-carboxylic acid building block. Of them, compound 8 was a tissue-nonspecific alkaline phosphatase (TNAP) inhibitor [22], compound 9 was an enkephalinase inhibitor [23], compound 10 was a mGlu5 receptor negative allosteric modulator and compounds 1 and 2 both were FXIa inhibitors [16,17,24]. Thus, novel FXIa inhibitors might be developed based on the excellent 5-phenyl-1*H*-pyrazole-3-carboxylic acid derivatives by using the Fragment Based Lead Generation strategy.




Figure 3. Representative pyrazole derivatives.

Furthermore, it was known that structure optimization using an optimal neutral P1 moiety could significantly facilitate identification of a potent, orally bioavailable FXIa inhibitor [25]. Taking these points into account, we replaced the P1 moiety in compound 3 with more neutral chloro-benzene leading to compound 7a and further modification of P1, P1' and P2' moieties in 7a furnished a series of 5-phenyl-1*H*-pyrazole-3-carboxamide FXIa inhibitors, of which the SAR was then systematically investigated (Figure 4).





Figure 4. Design of FXIa inhibitors in present study.

2. Results and Discussion


2.1. Chemistry

The synthetic route to target compounds **7a–7n** is shown in Scheme 1. The coupling of compound **12** with a series of carboxylic acids **11a–11n** afforded **13a–13n** in the presence of 1-hydroxybenzotriazole, *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride and *N,N*-diisopropyl-ethylamine in DMF, which were treated with LiOH·H₂O in aqueous methanol at 40 °C and acidified with 1 M hydrochloric acid to pH 3–4 to afford target compounds **7a–7n**.



Scheme 1. Synthetic route of compounds **7a–7n**. Reagents and conditions: (i) HOBT, EDCI, DIEA, DMF, r.t.; (ii) (1) LiOH·H₂O, MeOH, H₂O, 40 °C; (2) 1 M hydrochloric acid.


The synthetic route to target compounds **7o–7w** is summarized in Scheme 2. The intermediates **15o–15w** were prepared by the coupling of carboxylic acids **11f**, **11k**, **11m**, **11r** with amines **14a–14f** in the presence of 1-hydroxybenzotriazole, *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride and *N,N*-diisopropylethylamine in DMF, which were treated with LiOH·H₂O in aqueous ethanol at 40 °C. The resultant mixture was acidified with 1 M hydrochloric acid to pH 3–4 to afford target compounds **7o–7w**.



Scheme 2. Synthetic route of compounds **7o–7w**. Reagents and conditions: (i) HOBT, EDCI, DIEA, DMF, r.t.; (ii) (1) LiOH·H₂O, EtOH, H₂O, 40 °C; (2) 1 M hydrochloric acid.

The synthetic route to target compounds **7x–7y** is depicted in Scheme 3. Boc-Asp(OtBu)-OH (**16**) first reacted with ethyl 5-amino-1*H*-indole-2-carboxylate in the presence of POCl₃ and pyridine in CH₂Cl₂ to give the adduct **17**, which was deprotected with TFA/CH₂Cl₂ (1/1 by *v/v*), and treated with (Boc)₂O and Et₃N in CH₂Cl₂ to afford compound **18**. The coupling of carboxylic acid **18** with 1-(piperazin-1-yl)ethanone or morpholine yielded **19a** or **19b** in the presence of 1-hydroxybenzotriazole, *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride and *N,N*-diisopropylethylamine in DMF. Removal of N-Boc in **19a** with hydrochloric ethyl acetate and


the subsequent reaction with **11f** in the presence of 1-hydroxybenzotriazole, *N*-(3-dimethyl-aminopropyl)-*N'*-ethylcarbodiimide hydrochloride and *N,N*-diisopropylethylamine in DMF yielded **20a**. Hydrolysis of **20a** with LiOH·H₂O in aqueous ethanol and acidification with 1 M hydrochloric acid afforded **7t**. Compounds **20b** and **7u** were prepared according to the procedure described for the preparation of **20a** and **7t**.




Scheme 3. Synthetic route of compounds **7x–7y**. *Reagents and conditions:* (i) POCl₃, Pyridine, ethyl 5-amino-1*H*-indole-2-carboxylate, 0 °C; (ii) (1) TFA: CH₂Cl₂ = 1:1; (2) (Boc)₂O, Et₃N, CH₂Cl₂; (iii) for **19a**: 1-(piperazin-1-yl)ethanone, HOBT, EDCI, DIEA, DMF, r.t.; for **19b**: morpholine, HOBT, EDCI, DIEA, DMF, r.t.; (iv) (1) HCl/EtOAc, r.t.; (2) **11f**, HOBT, EDCI, DIEA, DMF, r.t.; (v) (1) LiOH·H₂O, EtOH, H₂O, r.t.; (2) 1 M hydrochloric acid.

The synthetic route to target compounds **7z**, **7za–7zc** is illustrated in Scheme 4. Coupling of carboxylic acid **11f** with amine **21** in the presence of 1-hydroxybenzotriazole, *N*-(3-dimethyl-aminopropyl)-*N'*-ethylcarbodiimide hydrochloride and *N,N*-diisopropylethylamine in DMF at room temperature, followed by the hydrolysis with LiOH·H₂O in aqueous methanol at room temperature, and subsequent acidification with 1 M hydrochloric acid afforded compound **22**. The coupling of compound **22** with ethyl 5-amino-1*H*-indole-2-carboxylate in the presence of POCl₃ and pyridine in CH₂Cl₂, and next reduction of NO₂ with H₂ (1 atm) in MeOH and ethyl acetate in the presence of Pd/C yielded compound **23**. Hydrolysis of ethyl ester with LiOH·H₂O in aqueous ethanol at 40 °C, and acidification of the resultant mixture with 1 M hydrochloric acid afforded target compounds **7z**. Compound **23** reacted with 2-methylcyclopropanecarboxylic acid in the presence of POCl₃ and pyridine in CH₂Cl₂ leading to **24za**. Reaction of **23** with 4-methylpiperazine-1-carbonyl chloride in the presence of pyridine and 4-dimethylaminopyridine in DMF afforded **24zb**. Compound **23** was coupled with 2-(2-chloroethoxy)acetic acid in the presence of *N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in THF, and the resultant product was treated with NaH in THF leading to **24zc**. Target compounds **7za–7zc** were synthesized from **24za–24zc** according to the procedure described for the preparation of **7z**.

The synthetic route to intermediates **11a–11n** and **11r** is shown in Scheme 5 according to relevant references [26]. **27a** first reacted with diethyl oxalate in the presence of LiHMDS in MTBE at 0 °C and the resultant mixture was acidified with hydrochloric acid (1 M) to yield **28a**. The cyclization of **28a** with hydrazine hydrate in EtOH at 80 °C yielded **29a**. The hydrolysis of **29a** with NaOH in EtOH and H₂O and acidification with 1 M hydrochloric acid afforded **11a**. The intermediates **11b–11n** and **11r** were synthesized from **27b–27n** according to the procedure described for the preparation of **11a**.




Scheme 4. Synthetic route of compounds **7z–7zc**. *Reagents and conditions:* (i) (1) **11f**, HOBT, EDCI, DIEA, DMF, r.t.; (2) LiOH·H₂O, MeOH, H₂O, r.t.; (3) 1 M hydrochloric acid; (ii) (1) ethyl 5-amino-1H-indole-2-carboxylate, HOBT, EDCI, DIEA, DMF, r.t.; (2) Pd/C, H₂, MeOH, EtOAc; (iii) for **24za**: 2-Methylcyclopropanecarboxylic acid, POCl₃, Pyridine, CH₂Cl₂, −10 °C; for **24zb**: 4-methylpiperazine-1-carbonyl chloride, Pyridine, DMAP, DMF; for **24zc**: (1) 2-(2-chloroethoxy)acetic acid, EEDQ, THF; (2) NaH, THF; (iv) (1) LiOH·H₂O, MeOH, H₂O, 40 °C; (2) 1 M hydrochloric acid.



Scheme 5. Synthetic route of compounds **11a–11n** and **11r**. *Reagents and conditions:* (i) (1) LiHMDS, Diethyl oxalate, MTBE, 0 °C; (2) 1 M hydrochloric acid; (ii) for **29a–29n**: hydrazine hydrate, EtOH, 80 °C; for **29r**: Methylhydrazine sulfate, EtOH, 80 °C; (iii) (1) NaOH, EtOH, H₂O, r.t.; (2) 1 M hydrochloric acid.

The synthetic route to intermediates **14a–14f** and **12** is depicted in Scheme 6 according to relevant references [18]. Compound **32** was prepared by the coupling of carboxylic acid **30** with amine **31** in the presence of POCl₃ and pyridine in CH₂Cl₂ at −10 °C. Removal of N-Boc of **32** with hydrochloric acid in ethyl acetate yielded compound **12**. The preparation of compound **14a–14f** followed the procedure described for the preparation of compound **12**.









Scheme 6. Synthetic route of compounds **14a–14f** and **12**. Reagents and conditions: (i) POCl₃, Pyridine, CH₂Cl₂, −10 °C; (ii) HCl/EtOAc.

2.2. Biological Activity and Discussion

2.2.1. In Vitro Inhibition Activity Studies on FXIa

In vitro FXIa affinity assay was used to examine the potency of **7a–7zc** against FXIa. As the effects of compound **4**, compound **3** and BMS-962212 (Figure 1) on FXIa activities were almost in the same degree (FXIa K_i = 0.7–3 nM) and they were all reported by Bristol-Myers Squibb Company, so whichever one was chosen as a positive control for in vitro FXIa affinity assays and activated partial prothrombin time (aPTT) coagulation assays is reasonable. Taking these points into account, compound **4** was used as a positive control in both assays. As shown in Table 1, **7a**, **7f**, **7k**, **7m** showed better potency for FXIa's inhibition than others in series of **7a–7n** with the same P1', P2' moiety and scaffold. Furthermore, **7m** showed weaker potency for FXIa's inhibition than **7a** but better potency than **7n**. Therefore, it can be inferred that **7m**'s -Me is a relatively better R₂ substitution than **7a**'s -H and **7n**'s -Et for FXIa's inhibition. For further optimization, the P2' moiety in **7f**, **7k** and **7m** was changed from the 4-aminobenzoic acid moiety to 5-amino-1*H*-indole-2-carboxylic acid moiety to give **7o**, **7p** and **7q**, respectively, of which **7o** possessed the best potency for FXIa's inhibition. Meanwhile, we also employed **7r**'s inhibition potency of FXIa which is different from **7q** at R₃ position (-Me substitution), and the results suggested that the R₃ substitution plays a minor role in the FXIa's inhibition. Based on above results, **7o** was chosen for further modification and the P1' moiety was replaced by 4 other groups. It's indicated that replacement of P1' moiety on **7o**' benzene with 4-fluorobenzo (**7s**) and 3-fluorobenzo (**7t**) improved the potency slightly (**7s** = 930.49 nM, **7t** = 1.66 μM, **7o** = 1.97 μM). The replacement of benzyl-type P1' moiety in **7o** with 4-pyridine, 3-pyridine or 2-pyridine (**7u**, **7v**, **7w**, respectively) was not benefit for potency as **7v**, **7u**, and **7w** showed reduced potency than **7o** (**7o** = 1.97 μM, **7v** = 3.52 μM, **7u** = 13.27 μM, **7w** = 8.99 μM). The replacement of the P1' moiety with carboxamide (**7x**, **7y**) was harmful for potency with 15 times reduction on potency (**7o** = 1.97 μM, **7x** = 81.18 μM, **7y** = 64.01 μM). At last, replacement of the P1' moiety in **7o** with 2-methylcyclopropanecarboxamide (**7za**) obviously improved the potency for more than 20 times (**7za** = 90.37 nM, **7o** = 1.97 μM). In addition, **7za** shows similar FXIa inhibitory potency as previously reported compound **4** (**7za** = 90.37 nM, **4** = 23.48 nM).

Table 1. Results of in vitro inhibitory assay of **7a–7zc** against FXIa (Ki).


Compound	R ₁	R ₂	R ₃	X, Y, Z	W	R ₄ or R ₅	Ki ^a
7a	3-chlorophenyl	H	H	--	--	--	46.66 μM
7b	phenyl	H	H	--	--	--	>84.46 μM
7c	2-fluorophenyl	H	H	--	--	--	>84.46 μM
7d	2-chlorophenyl	H	H	--	--	--	>84.46 μM
7e	4-chlorophenyl	H	H	--	--	--	>84.46 μM
7f	3-chloro-2-fluorophenyl	H	H	--	--	--	29.30 μM
7g	4-chloro-2-fluorophenyl	H	H	--	--	--	>84.46 μM
7h	5-chloro-2-fluorophenyl	H	H	--	--	--	>84.46 μM
7i	6-chloro-2-fluorophenyl	H	H	--	--	--	>84.46 μM
7j	2,6-difluorophenyl	H	H	--	--	--	>84.46 μM
7k	3-chloro-2,6-difluorophenyl	H	H	--	--	--	28.88 μM
7l	4-chloro-2,6-difluorophenyl	H	H	--	--	--	>84.46 μM
7m	3-chlorophenyl	Me	H	--	--	--	37.15 μM
7n	3-chlorophenyl	Et	H	--	--	--	>84.46 μM
7o	3-chloro-2-fluorophenyl	H	H	C,C,C	--	--	1.97 μM
7p	3-chloro-2,6-difluorophenyl	H	H	C,C,C	--	--	8.40 μM
7q	3-chlorophenyl	Me	H	C,C,C	--	--	8.94 μM
7r	3-chlorophenyl	Me	Me	C,C,C	--	--	11.43 μM
7s	3-chloro-2-fluorophenyl	H	H	C,C,C	4-F	--	930.49 nM
7t	3-chloro-2-fluorophenyl	H	H	C,C,C	3-F	--	1.66 μM
7u	3-chloro-2-fluorophenyl	H	H	C,C,N	--	--	13.27 μM
7v	3-chloro-2-fluorophenyl	H	H	C,N,C	--	--	3.52 μM
7w	3-chloro-2-fluorophenyl	H	H	N,C,C	--	--	8.99 μM
7x	--	--	--	--	--	R ₄ : 	81.18 μM
7y	--	--	--	--	--	R ₄ : 	64.01 μM
7z	--	--	--	--	--	R ₅ : -NH ₂	4.10 μM
7za	--	--	--	--	--	R ₅ : 	90.37 nM
7zb	--	--	--	--	--	R ₅ : 	1.94 μM
7zc	--	--	--	--	--	R ₅ : 	4.82 μM
4 ^b	--	--	--	--	--	--	23.48 nM

^a Ki = IC₅₀/(1 + [S]/Km); [S]: 435 μM, Km: 395 μM, Ki = IC₅₀/1.11; ^b Reported value for compound **4**: Ki = 3.0 nM against FXIa [18].

2.2.2. Activated Partial Prothrombin Time (aPTT) In Vitro Coagulation Assays

In order to assess the in vitro coagulation activity of compound **7za**, activated partial prothrombin time (aPTT) of **7za** and compound **4** was compared. As indicated in Table 2, **7za** showed good in vitro coagulation activity with 1.5× aPTT value of 43.33 μM in rabbit plasma.

Table 2.The anticoagulant activity of **7za**.

Compound	1.5 x aPTT (μM) (Rabbit)
7za	43.33
4	3.79

2.3. Molecular Model Studies on the Interaction of Compound **7za** with FXIa

Molecular docking method was used to study the binding mode of compound **7za** in the active site of FXIa. Two different binding modes of compound **7za** with FXIa were obtained (Figure 5a,b). Superposition of these two binding modes with the known compound **3** (Figure 5c,d) showed that **7za** in the second binding mode and known compound **3** overlay well (Figure 5d), indicating that this kind of binding model of **7za** with FXIa is more reasonable (Figure 5b). As designated, the 5-(3-chloro-2-fluorophenyl)-1H-pyrazole moiety is located deeply in S1 pocket of FXIa with the Cl atom forming an interaction with Tyr228, and the carbonyl group of 5-(3-chloro-2-fluorophenyl)-1H-pyrazole-3-carboxamide is well positioned within the oxyanion hole by forming key hydrogen bonds with Gly193 residues which is similar to the binding model of compound **3** with FXIa (Figure 5d). Furthermore, the 2-methylcyclopropanecarboxamide group of **7za** makes 2 direct hydrogen bonds with Tyr58B and Thr35 in the FXIa backbone, making **7za** binds to FXIa in a highly efficient manner (Figure 5b).




Figure 5. (a) Molecular model 1 of **7za** in active site of FXIa; (b) Molecular model 2 of **7za** in active site of FXIa; (c) Superposition of molecular mode 1 of **7za** with compound **3** (**7za**: yellow, compound **3**: purple); (d) Superposition of molecular mode 2 of **7za** with compound **3** (**7za**: yellow, compound **3**: purple).

3. Materials and Methods

3.1. General Information

Reagents and solvents were purchased from commercial suppliers and used without further purification. Reactions were monitored by thin layer chromatography. ^1H -NMR spectra (400 MHz) and ^{13}C -NMR (100 MHz) were recorded for DMSO- d_6 solutions on a Bruker spectrometer (Bruker, Billerica, MA, USA). MS were measured on a Finnigan LCQ Mass (Thermo Fisher Scientific, Waltham, MA, USA). HRMS were measured on a TOF LC/MS instrument (Agilent Technologies, Santa Clara, CA, USA).

3.2. Chemistry

Ethyl 2,4-dioxo-4-phenylbutanoate (28b): To a stirred solution of acetophenone (**27b**) (2.0 g, 16.5 mmol) in MTBE (30 mL) was added lithium hexamethyldisilazide (1.3 M, 12.7 mL, 16.5 mmol) dropwise at 0 °C; After addition, the reaction mixture was stirred at 0 °C for 0.5 h and diethyl oxalate (3.0 g, 20.8 mmol) was added dropwise. Then, the mixture was stirred at room temperature overnight. TLC analysis showed reaction was complete and the reaction mixture was extracted with H₂O (20 mL). The aqueous layer was separated, acidified by hydrochloric acid (1 M) to pH6 and extracted by ethyl acetate (10 mL \times 2). The combined organic layer was concentrated in vacuum to give **28b** as yellow oil, which was used for next step without further purification (3.4 g, 92.7% yield).

Ethyl 3-phenyl-1H-pyrazole-5-carboxylate (29b): To a solution of **28b** (3.4 g, 15.4 mmol) in EtOH (15 mL) was added hydrazine hydrate (1.2 g, 24.0 mmol) and the mixture was stirred at 50 °C for 2 h when TLC analysis indicated completion of reaction. Then the reaction mixture was evaporated to get crude **29b** as brown oil, which was used for next step without further purification (2.6 g, 77.9% yield).

5-Phenyl-1H-pyrazole-3-carboxylic acid (11b): To a solution of compound **29b** (2.6 g, 9.1 mmol) in MeOH (30 mL) and H₂O (15 mL) was added LiOH \cdot H₂O (0.5 g, 20.0 mmol) and the mixture was stirred at 70 °C for 8 h. The reaction mixture was evaporated and H₂O (15 mL) was added, then acidified by hydrochloric acid (1 M) to pH3. The suspension was filtered and washed by H₂O (10 mL), dried at 50 °C for 4 h to afford **11b** as a white solid (2.1g, 89.5% yield), m.p.: 227–229 °C, decomposition. ^1H -NMR: δ 13.39 (s, 1H), 7.83 (m, 2H), 7.41–7.45 (m, 2H), 7.31–7.35 (m, 1H), 7.18 (s, 1H). HRMS(ESI) calcd. For C₁₀H₈ClN₂O₂⁺: [M + H]⁺ m/z : 189.0659, found: 189.0659. The ^1H -NMR data were in good agreement with those reported [26].

Compounds **11a**, **11r** and **11c–11n** were synthesized according to the procedure described for the preparation of **11b**.

5-(3-Chlorophenyl)-1H-pyrazole-3-carboxylic acid (11a): white solid product (1.5 g, 47.9% yield), m.p.: 219–221 °C, decomposition. ^1H -NMR: δ 13.85–13.15 (m, 2H), 7.90 (m, 1H), 7.82–7.80 (d, J = 7.6 Hz, 1H), 7.47–7.37 (m, 2H), 7.29 (s, 1H). HRMS(ESI) calcd. For C₁₀H₉N₂O₂⁺: [M + H]⁺ m/z : 223.0269, found: 223.0268. The ^1H -NMR data were in good agreement with those reported [26].

3-(2-Fluorophenyl)-1H-pyrazole-5-carboxylic acid (11c): white solid product (2.3 g, 77.0% yield), m.p.: 232–234 °C, decomposition. ^1H -NMR: δ 13.84–13.52 (m, 2H), 7.94–7.91 (m, 1H), 7.43–7.38 (m, 1H), 7.34–7.27 (m, 2H), 7.05–7.04 (d, J = 3.6 Hz, 1H). HRMS(ESI) calcd. For C₁₀H₈FN₂O₂⁺: [M + H]⁺ m/z : 207.0564, found: 207.0563 [27].

3-(2-Chlorophenyl)-1H-pyrazole-5-carboxylic acid (11d): white solid product (1.8g, 62.5% yield), m.p.: 229–231 °C, decomposition. ^1H -NMR: δ 13.64–13.49 (m, 2H), 7.74 (s, 1H), 7.57–7.55 (m, 1H), 7.44–7.41 (m, 2H), 7.12 (s, 1H). HRMS(ESI) calcd. For C₁₀H₈ClN₂O₂⁺: [M + H]⁺ m/z : 223.0269, found: 223.0268 [27].

3-(4-Chlorophenyl)-1H-pyrazole-5-carboxylic acid (11e): white solid product (1.5 g, 52.1% yield), m.p.: 240–242 °C, decomposition. ¹H-NMR: δ 13.86–13.64 (m, 2H), 7.86–7.84 (d, *J* = 8.4 Hz, 2H), 7.49–7.47 (d, *J* = 8.4 Hz, 2H), 7.04 (s, 1H). HRMS(ESI) calcd. For C₁₀H₈ClN₂O₂⁺: [M + H]⁺ *m/z*: 223.0269, found: 223.0269. The ¹H-NMR data were in good agreement with those reported [26].

3-(3-Chloro-2-fluorophenyl)-1H-pyrazole-5-carboxylic acid (11f): white solid product (2.0 g, 71.7% yield), m.p.: 236–238 °C, decomposition. ¹H-NMR: δ 13.77 (m, 1H), 7.92–7.88 (m, 1H), 7.56–7.52 (m, 1H), 7.30–7.26 (m, 1H), 6.98–6.97 (d, *J* = 4.0 Hz, 1H). HRMS (ESI) calcd. For C₁₀H₇ClFN₂O₂⁺: [M + H]⁺ *m/z*: 241.0175, found: 241.0173.

3-(4-Chloro-2-fluorophenyl)-1H-pyrazole-5-carboxylic acid (11g): white solid product (1.9 g, 68.1% yield), m.p.: 234–236 °C, decomposition. ¹H-NMR: δ 13.07 (s, 1H), 7.98–7.93 (t, *J* = 8.4 Hz, 2H), 7.47–7.44 (qd, *J* = 2 Hz, 1H), 7.31–7.28 (qd, *J* = 2 Hz, 1H), 6.66–6.65 (d, *J* = 4.4 Hz, 1H). HRMS(ESI) calcd. For C₁₀H₇ClFN₂O₂⁺: [M + H]⁺ *m/z*: 241.0175, found: 241.0172.

3-(5-Chloro-2-fluorophenyl)-1H-pyrazole-5-carboxylic acid (11h): white solid product (1.5 g, 53.8% yield), m.p.: 229–231 °C, decomposition. ¹H-NMR: δ 14.11–13.42 (m, 2H), 7.97–7.95 (m, 1H), 7.47–7.36 (m, 2H), 7.10–7.05 (m, 1H). HRMS(ESI) calcd. For C₁₀H₇ClFN₂O₂⁺: [M + H]⁺ *m/z*: 241.0175, found: 241.0172.

3-(2-Chloro-6-fluorophenyl)-1H-pyrazole-5-carboxylic acid (11i): white solid product (1.6g, 57.4% yield), m.p.: 182–184 °C, decomposition. ¹H-NMR: δ 14.13–14.06 (m, 1H), 13.72–13.48 (m, 1H), 7.49–7.46 (m, 2H), 7.35 (m, 1H), 6.91 (s, 1H). HRMS(ESI) calcd. For C₁₀H₇ClFN₂O₂⁺: [M + H]⁺ *m/z*: 241.0175, found: 241.0170 [28].

3-(2,6-Difluorophenyl)-1H-pyrazole-5-carboxylic acid (11j): white solid product (1.6 g, 55.7% yield), m.p.: 232–334 °C, decomposition. ¹H-NMR: δ 14.08–13.05 (m, 2H), 7.53–7.46 (m, 1H), 7.25–7.21 (m, 2H), 6.98 (s, 1H). HRMS(ESI) calcd. For C₁₀H₇F₂N₂O₂⁺: [M + H]⁺ *m/z*: 225.0470, found: 241.0465.

3-(3-Chloro-2,6-difluorophenyl)-1H-pyrazole-5-carboxylic acid (11k): white solid product (1.2 g, 44.2% yield), m.p.: 233–235 °C, decomposition. ¹H-NMR: δ 14.17 (s, 1H), 7.72–7.67 (m, 1H), 7.33–7.29 (m, 1H), 7.02 (s, 1H). HRMS(ESI) calcd. For C₁₀H₆ClF₂N₂O₂⁺: [M + H]⁺ *m/z*: 259.0080, found: 259.0074.

3-(4-Chloro-2,6-difluorophenyl)-1H-pyrazole-5-carboxylic acid (11l): white solid product (1.6 g, 58.9% yield), m.p.: 238–240 °C, decomposition. ¹H-NMR: δ 13.64 (s, 1H), 7.51–7.49 (d, *J* = 8.0 Hz, 2H), 6.99 (s, 1H). HRMS(ESI) calcd. For C₁₀H₆ClF₂N₂O₂⁺: [M + H]⁺ *m/z*: 259.0080, found: 259.0078.

5-(3-Chlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid (11m): white solid product (1.1 g, 39.2% yield), m.p.: 226–228 °C, decomposition. ¹H-NMR: δ 13.64–13.57 (m, 2H), 7.66 (s, 1H), 7.63–7.57 (m, 1H), 7.51–7.42 (m, 2H), 2.39(s, 3H). HRMS(ESI) calcd. For C₁₁H₁₀ClN₂O₂⁺: [M + H]⁺ *m/z*: 237.0425, found: 237.0424.

5-(3-Chlorophenyl)-4-ethyl-1H-pyrazole-3-carboxylic acid (11n): white solid product (0.2 g, 7.3% yield), m.p.: 236–238 °C, decomposition. ¹H-NMR: δ 13.43 (s, 1H), 7.58(s, 1H), 7.53–7.43(m, 3H), 2.82–2.76 (qd, *J* = 7.2 Hz, 2H), 1.12–1.08 (m, 3H). HRMS(ESI) calcd. For C₁₂H₁₂ClN₂O₂⁺: [M + H]⁺ *m/z*: 251.0582, found: 251.0577.

5-(3-Chlorophenyl)-1,4-dimethyl-1H-pyrazole-3-carboxylic acid (11r): white solid product (1.1 g, 37.0% yield), m.p.: 147–149 °C, decomposition. ¹H-NMR: δ 12.52 (s, 1H), 7.56–7.54 (m, 3H), 7.41–7.39 (m, 1H), 3.74 (s, 3H), 2.10 (s, 3H). The structure was confirmed by NOESY.HRMS(ESI) calcd.For C₁₂H₁₂ClN₂O₂⁺: [M + H]⁺ *m/z*: 251.0582, found: 251.0575.

(S)-Methyl-4-(2-((tert-butoxycarbonyl)amino)-3-phenylpropanamido)benzoate (32): To a stirred mixture of Boc-Phe-OH (30) (10.0 g, 37.7mmol), methyl 4-aminobenzoate (31) (5.7 g, 37.7 mmol) and pyridine

(10 mL) in CH_2Cl_2 (100 mL) at $-10\text{ }^\circ\text{C}$ was added POCl_3 (5.8 g, 37.7 mmol) dropwise. After addition, the reaction mixture was stirred at $0\text{ }^\circ\text{C}$ for 2 h when TLC analysis indicated completion of reaction, then H_2O (20 mL) was added and the organic layer was separated, washed by hydrochloric acid (1 M, 20 mL), dried by Na_2SO_4 , filtered. The filtrate was evaporated in vacuum to get crude **32** as a yellow solid, which was used for next step without further purification (11.6 g, 77.3% yield).

(S)-Methyl-4-(2-amino-3-phenylpropanamido)benzoate hydrochloride (**12**): To a solution of compound **32** (11.5 g, 28.9 mmol) in ethyl acetate (50 mL) was added hydrochloric/ethyl acetate (50 mL, saturated solution), and the mixture was stirred at room temperature overnight. Then TLC analysis showed reaction was complete. The suspension was filtered and the filter cake was washed by ethyl acetate (20 mL), dried at $50\text{ }^\circ\text{C}$ for 4 h to afford **12** as a pink solid (8.2 g, 84.3% yield), m.p.: $127\text{--}129\text{ }^\circ\text{C}$. $^1\text{H-NMR}$: δ 11.27 (s, 1H), 8.45 (s, 3H), 7.93–7.91 (d, $J = 8.4\text{ Hz}$, 2H), 7.73–7.71 (d, $J = 8.8\text{ Hz}$, 2H), 7.32–7.23 (m, 5H), 4.34 (m, 1H), 3.81 (s, 3H), 3.24–3.12 (m, 2H). ESI-MS (m/z) = 299.09 $[\text{M} + \text{H}]^+$.

(S)-Ethyl 5-(2-((tert-butoxycarbonyl)amino)-3-phenylpropanamido)-1H-indole-2-carboxylate (**35a**): To a mixture of Boc-Phe-OH (**33a**) (5 g, 18.9 mmol), ethyl 5-amino-1H-indole-2-carboxylate (**34**) (3.9 g, 18.9 mmol) and pyridine (5 mL) in CH_2Cl_2 (50 mL) at $-10\text{ }^\circ\text{C}$ was added POCl_3 (2.9 g, 18.9 mmol) dropwise. After addition, the reaction mixture was stirred at $-10\text{ }^\circ\text{C}$ for 2 h when TLC analysis indicated completion of reaction, then H_2O (10 mL) was added and the organic layer was separated, washed by hydrochloric acid (1 M, 10 mL), dried by Na_2SO_4 , filtered. The filtrate was evaporated in vacuum to get crude **35a** as a brown solid, which was used for next step without further purification (6.6 g, 77.6% yield).

(S)-Ethyl 5-(2-amino-3-phenylpropanamido)-1H-indole-2-carboxylate hydrochloride (**14a**): To a solution of compound **35a** (6.5 g, 14.4 mmol) in ethyl acetate (15 mL) was added hydrochloric/ethyl acetate (30 mL, saturated solution), and the mixture was stirred at room temperature overnight. Then TLC analysis showed reaction was complete. The suspension was filtered and the filter cake was washed by ethyl acetate (20 mL) and dried at $50\text{ }^\circ\text{C}$ for 4 h to afford **14a** as a grey solid (4.9 g, 87.7% yield), m.p.: $135\text{--}137\text{ }^\circ\text{C}$, decomposition. $^1\text{H-NMR}$: δ 11.86 (s, 1H), 10.46 (s, 1H), 8.36–8.32 (m, 4H), 7.91 (s, 1H), 7.33–7.12 (m, 8H), 4.35–4.29 (m, 2H), 4.19 (m, 1H), 3.13–3.08 (m, 2H), 1.34–1.31 (m, 3H). ESI-MS (m/z) = 352.10 $[\text{M} + 1]^+$ [18].

Compounds **14b–14f** were synthesized according to the procedure described for the preparation of **14a**.

(S)-Ethyl 5-(2-amino-3-(4-fluorophenyl)propanamido)-1H-indole-2-carboxylate hydrochloride (**14b**): grey solid product (4.0 g, 52.3% yield), m.p.: $243\text{--}245\text{ }^\circ\text{C}$, decomposition. $^1\text{H-NMR}$: δ 11.85 (s, 1H), 10.84 (s, 1H), 8.45 (s, 2H), 7.96 (s, 1H), 7.41–7.36 (m, 4H), 7.15–7.11 (m, 3H), 4.36–4.29 (m, 2H), 3.15–3.09 (m, 2H), 1.34–1.30 (m, 3H). ESI-MS (m/z) = 370.06 $[\text{M} + 1]^+$ [29].

(S)-Ethyl 5-(2-amino-3-(3-fluorophenyl)propanamido)-1H-indole-2-carboxylate hydrochloride (**14c**): grey solid product (3.7 g, 48.6% yield), m.p.: $154\text{--}156\text{ }^\circ\text{C}$, decomposition. $^1\text{H-NMR}$: δ 11.86 (s, 1H), 10.77 (s, 1H), 8.43 (s, 3H), 7.95 (s, 1H), 7.41–7.32 (m, 3H), 7.22–7.05 (m, 4H), 4.35–4.02 (m, 3H), 3.37–3.11 (m, 2H), 1.35–1.31 (t, $J = 6.8\text{ Hz}$, 3H). ESI-MS (m/z) = 370.02 $[\text{M} + 1]^+$, HRMS(ESI) calcd. For $\text{C}_{20}\text{H}_{21}\text{FN}_3\text{O}_3^+$: $[\text{M} + \text{H}]^+ m/z$: 370.1561, found: 370.1553.

(S)-Ethyl 5-(2-amino-3-(pyridin-4-yl)propanamido)-1H-indole-2-carboxylate hydrochloride (**14d**): grey solid product (0.5 g, 6.8%), m.p.: $171\text{--}173\text{ }^\circ\text{C}$, decomposition. $^1\text{H-NMR}$: δ 11.87 (s, 1H), 11.32 (s, 1H), 8.88–8.86 (d, $J = 6.4\text{ Hz}$, 2H), 8.59 (s, 3H), 8.13–8.11 (d, $J = 5.6\text{ Hz}$, 2H), 8.03 (s, 1H), 7.47–7.40 (m, 2H), 7.12 (s, 1H), 4.57 (s, 1H), 4.35–4.29 (qd, $J = 6.8\text{ Hz}$ and 7.2 Hz , 2H), 3.65–3.62 (m, 1H), 3.41–3.35 (m, 1H), 1.34–1.30 (t, $J = 7.2\text{ Hz}$, 3H). ESI-MS (m/z) = 353.00 $[\text{M} + 1]^+$, HRMS(ESI) calcd. For $\text{C}_{19}\text{H}_{21}\text{N}_4\text{O}_3^+$: $[\text{M} + \text{H}]^+ m/z$: 353.1608, found: 353.1602.

(*S*)-Ethyl 5-(2-amino-3-(pyridin-3-yl)propanamido)-1*H*-indole-2-carboxylate hydrochloride (**14e**): grey solid product (1.5 g, 19.2%). ¹H-NMR: δ 11.90 (s, 1H), 11.07 (s, 1H), 8.89 (s, 1H), 8.79–8.77 (d, *J* = 5.6 Hz, 1H), 8.48–8.43 (m, 4H), 8.00 (s, 1H), 7.91–7.88 (t, *J* = 6.4 Hz, 1H), 7.40 (s, 1H), 7.13 (s, 1H), 4.47 (s, 1H), 4.35–4.29 (m, 2H), 3.52–3.47 (m, 1H), 3.32–3.26 (m, 1H), 1.34–1.30 (m, 3H). ESI-MS (*m/z*) = 353.15 [*M* + 1]⁺.

(*S*)-Ethyl 5-(2-amino-3-(pyridin-2-yl)propanamido)-1*H*-indole-2-carboxylate hydrochloride (**14f**): grey solid product (1.8 g, 24.6%), m.p.: 75–77 °C, decomposition. ¹H-NMR: δ 11.86 (s, 1H), 10.89 (s, 1H), 8.76–8.75 (d, *J* = 5.2 Hz, 1H), 8.65 (s, 3H), 8.21–8.19 (m, 1H), 7.97 (s, 1H), 7.81–7.79 (d, *J* = 7.6 Hz, 1H), 7.69–7.67 (m, 1H), 7.42–7.38 (m, 2H), 7.11 (s, 1H), 4.60 (s, 1H), 4.35–4.29 (m, 2H), 3.63–3.54 (m, 2H), 1.34–1.30 (t, *J* = 7.2 Hz, 3H). ESI-MS (*m/z*) = 353.05 [*M* + 1]⁺, HRMS(ESI) calcd. For C₁₉H₂₁N₄O₃⁺: [*M* + H]⁺ *m/z*: 353.1608, found: 353.1604.

(*S*)-Methyl 4-(2-(5-(3-chlorophenyl)-1*H*-pyrazole-3-carboxamido)-3-phenylpropanamido)benzoate (**13a**): To a mixture of 3-(3-chlorophenyl)-1*H*-pyrazole-5-carboxylic acid (**14a**, 133 mg, 0.60 mmol) in DMF (4 mL) was added (*S*)-methyl-4-(2-amino-3-phenylpropanamido)benzoate hydrochloride (**12**, 200 mg, 0.60 mmol), *N,N*-diisopropyl-ethylamine (232 mg, 1.80 mmol), 1-hydroxybenzotriazole (161 mg, 1.20 mmol) and *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride (229 mg, 1.20 mmol) and the reaction mixture was stirred at room temperature overnight. Then TLC analysis indicated reaction was complete, and H₂O (40 mL) was added. The mixture was stirred for 10 min and filtered to get crude product **13a** as a yellow solid, which was used for next step without further purification.

(*S*)-4-(2-(5-(3-Chlorophenyl)-1*H*-pyrazole-3-carboxamido)-3-phenylpropanamido)benzoic acid (**7a**): To a mixture of compound **13a** (289 mg, 0.60 mmol) in MeOH (3 mL) and H₂O (1.5 mL) was added LiOH·H₂O (100 mg, 2.40 mmol) and the reaction mixture was stirred at 40 °C for 6 h when TLC analysis indicated completion of reaction. The mixture was evaporated in vacuum and H₂O (2 mL) was added, extracted by MTBE (2 mL) and acidified by hydrochloric acid (1 M) to pH 3–4. After stirred for 0.5 h, the suspension was filtered, and the filter cake washed by H₂O (5 mL) and dried at 50 °C for 2 h to afford **7a** as a white solid (185 mg, 63.4% yield for 2 steps); m.p.: 147–149 °C, decomposition. ¹H-NMR: δ 13.68 (s, 1H), 12.65 (s, 1H), 10.57 (s, 1H), 7.93–7.88 (m, 3H), 7.73–7.71 (m, 2H), 7.60–7.15 (m, 8H), 4.93–4.88 (m, 1H), 3.31–3.15 (m, 2H). ¹³C-NMR: δ 170.64, 167.03, 142.99, 137.61, 133.84, 130.88, 130.43, 129.34, 129.20, 128.20, 127.94, 126.51, 125.55, 124.88, 123.91, 118.78, 103.51, 55.29, 37.46. ESI-MS (*m/z*) = 488.90 [*M* + H]⁺, HRMS(ESI) calcd. For C₂₆H₂₂ClN₄O₄⁺: [*M* + H]⁺ *m/z*: 489.1324, found: 489.1317.

Compounds **7b**–**7n** were synthesized according to the procedure described for the preparation of **7a**.

(*S*)-4-(3-Phenyl-2-(5-phenyl-1*H*-pyrazole-3-carboxamido)propanamido)benzoic acid (**7b**): white solid product (183 mg, 67.4% yield), m.p.: 137–139 °C, decomposition. ¹H-NMR: δ 13.68–13.64 (m, 1H), 12.76–12.70 (m, 1H), 10.52 (s, 1H), 8.11–8.09 (m, 1H), 7.91–7.88 (d, *J* = 8.4 Hz, 2H), 7.77–7.70 (m, 4H), 7.46–7.43 (m, 2H), 7.34–7.19 (m, 5H), 7.17–7.09 (m, 1H), 7.06 (s, 1H), 4.93–4.87 (m, 1H), 3.16–3.15 (m, 2H). ¹³C-NMR: δ 171.25, 167.67, 161.28, 143.49, 138.15, 131.10, 129.92, 129.82, 129.62, 128.84, 127.16, 126.24, 125.92, 119.42, 103.42, 55.67, 38.12. ESI-MS (*m/z*) = 454.99 [*M* + H]⁺, HRMS(ESI) calcd. For C₂₆H₂₃N₄O₄⁺: [*M* + H]⁺ *m/z*: 455.1714, found: 455.1703.

(*S*)-4-(2-(5-(2-Fluorophenyl)-1*H*-pyrazole-3-carboxamido)-3-phenylpropanamido)benzoic acid (**7c**): white solid product (220 mg, 77.9% yield), m.p.: 86–88 °C, decomposition. ¹H-NMR: δ 13.76–13.69 (m, 1H), 12.79–12.68 (m, 1H), 10.57 (s, 1H), 9.02–8.97 (m, 1H), 7.90–7.88 (d, *J* = 8.8 Hz, 2H), 7.73–7.71 (d, *J* = 8.4 Hz, 2H), 7.39–7.17 (m, 8H), 7.15–7.07 (m, 1H), 7.00 (s, 1H), 4.93–4.87 (m, 1H), 3.23–3.15 (m, 2H). ESI-MS (*m/z*) = 472.99 [*M* + H]⁺. ¹³C-NMR: δ 171.38, 167.65, 160.65, 143.73, 138.34, 130.98, 130.70, 130.01, 129.79, 128.75, 127.08, 126.09, 125.49, 119.39, 116.81, 106.49, 56.03, 37.90. HRMS(ESI) calcd. For C₂₆H₂₂FN₄O₄⁺: [*M* + H]⁺ *m/z*: 473.1620, found: 473.1600.

(*S*)-4-(2-(5-(2-Chlorophenyl)-1H-pyrazole-3-carboxamido)-3-phenylpropanamido)benzoic acid (**7d**): white solid product (221 mg, 75.7% yield), m.p.: 92–94 °C, decomposition. ¹H-NMR: δ 13.31 (s, 1H), 10.95 (s, 1H), 8.68 (s, 1H), 7.94–7.92 (d, *J* = 8.8 Hz, 2H), 7.84–7.82 (d, *J* = 8.4 Hz, 2H), 7.74–7.72 (d, *J* = 6.8 Hz, 1H), 7.55–7.53 (d, *J* = 7.2 Hz, 1H), 7.42–7.35 (m, 4H), 7.31–7.22 (m, 3H), 7.17–7.14 (m, 1H), 5.01–4.95 (m, 1H), 3.28–3.11 (m, 2H). ¹³C-NMR: δ 172.94, 170.79, 167.03, 143.12, 137.74, 131.15, 130.57, 129.94, 129.40, 129.19, 128.30, 127.53, 126.54, 125.47, 118.82, 106.57, 55.39, 36.41. ESI-MS (*m/z*) = 489.01 [*M* + *H*]⁺, HRMS(ESI) calcd. For C₂₆H₂₂ClN₄O₄⁺: [*M* + *H*]⁺ *m/z*: 489.1324, found: 489.1309.

(*S*)-4-(2-(5-(4-Chlorophenyl)-1H-pyrazole-3-carboxamido)-3-phenylpropanamido)benzoic acid (**7e**): white solid product (177 mg, 60.3% yield), m.p.: 174–176 °C, decomposition. ¹H-NMR: δ 13.74–13.63 (m, 1H), 12.66 (s, 1H), 10.49 (s, 1H), 10.37 (s, 1H), 7.91–7.86 (t, *J* = 8.8 Hz, 2H), 7.80–7.78 (d, *J* = 8.0 Hz, 1H), 7.72–7.67 (m, 2H), 7.51 (s, 2H), 7.27–7.15 (m, 6H), 7.08 (s, 1H), 4.90–4.89 (m, 1H), 3.17–3.15 (m, 2H). ¹³C-NMR: δ 170.59, 168.12, 160.16, 142.37, 137.66, 132.74, 130.36, 129.35, 129.02, 128.23, 127.97, 127.58, 127.04, 126.54, 118.72, 103.22, 55.37, 37.50. ESI-MS (*m/z*) = 488.89 [*M* + *H*]⁺, HRMS(ESI) calcd. For C₂₆H₂₂ClN₄O₄⁺: [*M* + *H*]⁺ *m/z*: 489.1324, found: 489.1311.

(*S*)-4-(2-(5-(3-Chloro-2-fluorophenyl)-1H-pyrazole-3-carboxamido)-3-phenylpropanamido)benzoic acid (**7f**): white solid product (258 mg, 84.8% yield), m.p.: 185–187 °C, decomposition. ¹H-NMR: δ 13.86 (s, 1H), 12.69 (s, 1H), 10.54 (s, 1H), 10.38 (s, 1H), 8.31–8.29 (d, *J* = 8.0 Hz, 1H), 7.91–7.86 (m, 2H), 7.73–7.67 (m, 2H), 7.57 (s, 1H), 7.35–7.19 (m, 5H), 7.17–7.15 (m, 1H), 4.91–4.89 (m, 1H), 3.16–2.99 (m, 1H), 2.86–2.81 (m, 1H). ¹³C-NMR: δ 170.70, 168.35, 159.87, 155.44, 142.28, 137.77, 130.47, 129.42, 128.36, 128.00, 127.03, 126.68, 125.87, 121.01, 118.85, 106.21, 55.55, 37.46. ESI-MS (*m/z*) = 506.93 [*M* + *H*]⁺, HRMS(ESI) calcd. For C₂₆H₂₁ClFN₄O₄⁺: [*M* + *H*]⁺ *m/z*: 507.1230, found: 507.1220.

(*S*)-4-(2-(5-(4-Chloro-2-fluorophenyl)-1H-pyrazole-3-carboxamido)-3-phenylpropanamido)benzoic acid (**7g**): white solid product (220 mg, 72.6% yield), m.p.: 143–145 °C, decomposition. ¹H-NMR: δ 13.82 (s, 1H), 12.70 (s, 1H), 10.55 (s, 1H), 9.00 (s, 1H), 7.94 (s, 1H), 7.90–7.88 (d, *J* = 8.4 Hz, 2H), 7.73–7.71 (d, *J* = 8.4 Hz, 2H), 7.58–7.56 (m, 1H), 7.35–7.27 (m, 3H), 7.26–7.24 (m, 2H), 7.18–7.15 (m, 1H), 4.93–4.87 (m, 1H), 3.18–3.11 (m, 2H). ¹³C-NMR: δ 171.27, 167.62, 160.54, 158.03, 143.55, 138.26, 133.94, 131.04, 129.91, 128.78, 127.11, 126.15, 125.80, 119.39, 117.65, 106.48, 55.92, 37.90. HRMS (ESI) calcd. For C₂₆H₂₁ClFN₄O₄⁺: [*M* + *H*]⁺ *m/z*: 507.1230, found: 507.1215.

(*S*)-4-(2-(5-(5-Chloro-2-fluorophenyl)-1H-pyrazole-3-carboxamido)-3-phenylpropanamido)benzoic acid (**7h**): grey solid product (176 mg, 57.9% yield), m.p.: 179–181 °C, decomposition. ¹H-NMR: δ 13.89–13.83 (m, 1H), 12.78 (s, 1H), 10.55 (s, 1H), 8.78–8.77 (m, 1H), 7.96–7.94 (m, 1H), 7.90–7.88 (d, *J* = 8.8 Hz, 2H), 7.71–7.69 (d, *J* = 8.4 Hz, 2H), 7.47–7.18 (m, 6H), 7.16–7.15 (m, 1H), 4.92–4.87 (m, 1H), 3.19–3.07 (m, 2H). ¹³C-NMR: δ 171.21, 168.05, 159.40, 143.20, 138.31, 130.98, 129.88, 129.5, 128.80, 127.73, 127.11, 119.32, 119.13, 118.89, 106.79, 55.95, 37.90. ESI-MS (*m/z*) = 506.87 [*M* + *H*]⁺, HRMS(ESI) calcd. For C₂₆H₂₁ClFN₄O₄⁺: [*M* + *H*]⁺ *m/z*: 507.1230, found: 507.1221.

(*S*)-4-(2-(5-(2-Chloro-6-fluorophenyl)-1H-pyrazole-3-carboxamido)-3-phenylpropanamido)benzoic acid (**7i**): white solid product (189 mg, 62.1% yield), m.p.: 203–205 °C, decomposition. ¹H-NMR: δ 13.74–13.70 (m, 1H), 10.64 (s, 1H), 7.89–7.87 (d, *J* = 8.8 Hz, 2H), 7.71–7.69 (d, *J* = 8.4 Hz, 2H), 7.54–7.42 (m, 2H), 7.38–7.36 (m, 3H), 7.28–7.24 (m, 2H), 7.19–7.15 (m, 1H), 7.08–6.98 (m, 1H), 4.92–4.86 (m, 1H), 3.21–3.09 (m, 2H). ¹³C-NMR: δ 171.31, 168.49, 162.00, 143.11, 138.33, 134.48, 130.98, 129.94, 128.82, 127.69, 127.14, 126.53, 119.26, 115.63, 115.40, 108.35, 56.03, 37.88. ESI-MS (*m/z*) = 506.88 [*M* + *H*]⁺, HRMS(ESI) calcd. For C₂₆H₂₁ClFN₄O₄⁺: [*M* + *H*]⁺ *m/z*: 507.1230, found: 507.1213.

(*S*)-4-(2-(5-(2,6-Difluorophenyl)-1H-pyrazole-3-carboxamido)-3-phenylpropanamido)benzoic acid (**7j**): white solid product (153 mg, 50.6% yield), m.p.: 205–207 °C, decomposition. ¹H-NMR: δ 13.66 (s, 1H), 12.79–12.70 (m, 1H), 10.54 (s, 1H), 7.91–7.89 (d, *J* = 8.4 Hz, 2H), 7.73–7.70 (d, *J* = 8.4 Hz, 2H), 7.50 (s, 1H), 7.35–7.03 (m, 6H), 7.03–6.99 (m, 2H), 4.91–4.89 (m, 1H), 3.16–3.15 (m, 2H). ¹³C-NMR: δ 170.65, 166.99, 160.63, 160.18, 158.08, 142.90, 137.62, 130.76, 130.46, 129.27, 128.20, 126.51, 125.53, 118.77,

112.31, 107.44, 55.16, 37.34. ESI-MS (m/z) = 490.98 $[M + H]^+$, HRMS(ESI) calcd. For $C_{26}H_{21}F_2N_4O_4^+$: $[M + H]^+$ m/z : 491.1525, found: 491.1500.

(*S*)-4-(2-(5-(3-Chloro-2,6-difluorophenyl)-1H-pyrazole-3-carboxamido)-3-phenylpropanamido)benzoic acid (**7k**): white solid product (220 mg, 70.2% yield), m.p.: 129–131 °C, decomposition. 1H -NMR: δ 13.80 (s, 1H), 12.74 (s, 1H), 10.53 (s, 1H), 7.91–7.89 (d, J = 8.4 Hz, 2H), 7.73–7.70 (m, 3H), 7.34–7.04 (m, 8H), 4.93–4.87 (m, 1H), 3.18–3.15 (m, 2H). ^{13}C -NMR: δ 171.23, 167.60, 157.27, 143.45, 138.22, 131.08, 129.86, 128.81, 127.13, 126.20, 119.39, 117.07, 113.99, 113.77, 108.30, 55.82, 37.94. ESI-MS (m/z) = 525.00 $[M + H]^+$, HRMS(ESI) calcd. For $C_{26}H_{20}ClF_2N_4O_4^+$: $[M + H]^+$ m/z : 525.1136, found: 525.1116.

(*S*)-4-(2-(5-(4-Chloro-2,6-difluorophenyl)-1H-pyrazole-3-carboxamido)-3-phenylpropanamido)benzoic acid (**7l**): white solid product (220 mg, 70.2% yield), m.p.: 123–125 °C, decomposition. 1H -NMR: δ 13.93–13.77 (m, 1H), 12.78–12.72 (m, 1H), 10.59 (s, 1H), 9.04–9.02 (m, 1H), 7.91–7.89 (d, J = 8.8 Hz, 2H), 7.73–7.71 (d, J = 8.8 Hz, 2H), 7.54 (s, 2H), 7.36–7.34 (m, 2H), 7.27–7.24 (m, 2H), 7.18–7.10 (m, 1H), 6.99–6.96 (m, 1H), 4.91–4.86 (m, 1H), 3.17–3.14 (m, 2H). ^{13}C -NMR: δ 171.30, 167.68, 158.58, 143.52, 138.27, 131.07, 129.91, 128.80, 127.13, 126.19, 119.34, 114.11, 113.83, 108.14, 55.92, 37.86. ESI-MS (m/z) = 525.01 $[M + H]^+$, HRMS(ESI) calcd. For $C_{26}H_{20}ClF_2N_4O_4^+$: $[M + H]^+$ m/z : 525.1136, found: 525.1126.

(*S*)-4-(2-(5-(3-Chlorophenyl)-4-methyl-1H-pyrazole-3-carboxamido)-3-phenylpropanamido)benzoic acid (**7m**): white solid product (29 mg, 9.8% yield), m.p.: 164–166 °C, decomposition. 1H -NMR: δ 13.48 (s, 1H), 12.70 (s, 1H), 10.48 (s, 1H), 8.01–7.98 (m, 1H), 7.91–7.89 (m, 2H), 7.71–7.69 (m, 2H), 7.60 (s, 1H), 7.54–7.49 (m, 3H), 7.29–7.21 (m, 4H), 7.21–7.19 (m, 1H), 4.90–4.88 (m, 1H), 3.17–3.15 (m, 2H), 2.29 (s, 3H). ESI-MS (m/z) = 503.00 $[M + H]^+$, HRMS(ESI) calcd. For $C_{27}H_{24}ClN_4O_4^+$: $[M + H]^+$ m/z : 503.1481, found: 503.1467.

(*S*)-4-(2-(5-(3-Chlorophenyl)-4-ethyl-1H-pyrazole-3-carboxamido)-3-phenylpropanamido)benzoic acid (**7n**): white solid product (227 mg, 73.5% yield), m.p.: 126–128 °C, decomposition. 1H -NMR: δ 13.46 (s, 1H), 12.74 (s, 1H), 10.54 (s, 1H), 8.01 (s, 1H), 7.91–7.89 (d, J = 8.4 Hz, 2H), 7.72–7.70 (d, J = 8.8 Hz, 2H), 7.54–7.45 (m, 4H), 7.31–7.24 (m, 4H), 7.20–7.16 (m, 1H), 4.93–4.88 (qd, J = 8.0 Hz, 1H), 3.21–3.10 (m, 2H), 2.75–2.69 (qd, J = 7.2 Hz, 2H), 1.04–1.01 (m, 3H). ESI-MS (m/z) = 516.91 $[M + H]^+$, HRMS(ESI) calcd. For $C_{28}H_{26}ClN_4O_4^+$: $[M + H]^+$ m/z : 517.1637, found: 517.1624.

(*S*)-Ethyl

5-(2-(3-(3-chloro-2-fluorophenyl)-1H-pyrazole-5-carboxamido)-3-phenylpropanamido)-1H-indole-2-carboxylate (**15o**): To a mixture of 3-(3-chloro-2-fluorophenyl)-1H-pyrazole-5-carboxylic acid (**11f**, 136 mg, 0.57 mmol) in DMF (3 mL) was added 1-hydroxybenzotriazole (139 mg, 1.04 mmol), (*S*)-ethyl 5-(2-amino-3-phenylpropanamido)-1H-indole-2-carboxylate hydrochloride (**14a**, 200 mg, 0.52 mmol), *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride (198 mg, 1.04 mmol) and *N,N*-diisopropylethylamine (200 mg, 1.56 mmol), then the reaction mixture was stirred at room temperature overnight. TLC analysis indicated reaction was complete and H_2O (30 mL) was added. The suspension was stirred for 0.5 h and filtered. The filter cake was washed by H_2O (5 mL) to get crude product **15o** (130 mg, 44.2% yield) as a brown solid, which was used for next step without further purification.

(*S*)-5-(2-(3-(3-Chloro-2-fluorophenyl)-1H-pyrazole-5-carboxamido)-3-phenylpropanamido)-1H-indole-2-carboxylic acid (**7o**): To a suspension of compound **15o** (130 mg, 0.23 mmol) in EtOH (3 mL) and H_2O (1.5 mL) was added LiOH· H_2O (38 mg, 0.92 mmol) and the reaction mixture was stirred at 40 °C for 6 h when TLC analysis indicated completion of reaction. The reaction mixture was evaporated on a rotary evaporator in vacuum and H_2O (4 mL) was added. The solution was extracted by MTBE (2 mL), acidified by hydrochloric acid (1 M) to pH 3–4. After stirred for 0.5 h, the suspension was filtered, washed by H_2O (5 mL) and the filter cake was dried at 50 °C for 2 h to afford **7o** as a white solid (112 mg, 39.6% yield for 2 steps), m.p.: 172–174 °C, decomposition. 1H -NMR: δ 13.84 (s, 1H), 12.81 (s, 1H), 11.67 (s, 1H), 10.11 (s, 1H), 7.98 (s, 1H), 7.88 (s, 1H), 7.58 (s, 1H), 7.52–7.11 (m, 11H), 7.04

(s, 1H), 4.93–4.87 (m, 1H), 3.20–3.10 (m, 2H). HRMS(ESI) calcd. for $C_{28}H_{22}ClFN_5O_4^+$: $[M + H]^+ m/z$: 546.1339, found: 546.1325.

Compounds **7p**–**7w** were synthesized according to the procedure described for the preparation of **7o**.

(*S*)-5-(2-(3-(3-Chloro-2,6-difluorophenyl)-1H-pyrazole-5-carboxamido)-3-phenylpropanamido)-1H-indole-2-carboxylic acid (**7p**): white solid product (91 mg, 31.2% yield), m.p.: 164–166 °C, decomposition. 1H -NMR: δ 13.96 (s, 1H), 12.98 (s, 1H), 11.61 (s, 1H), 10.30 (s, 1H), 8.93 (s, 1H), 7.96 (s, 1H), 7.85 (s, 1H), 7.71–7.17 (m, 9H), 6.99 (s, 1H), 4.90–4.89 (m, 1H), 3.20–3.16 (m, 2H). ESI-MS (m/z) = 563.87 $[M + H]^+$, HRMS(ESI) calcd. For $C_{28}H_{21}ClF_2N_5O_4^+$: $[M + H]^+ m/z$: 564.1245, found: 564.1234.

(*S*)-5-(2-(3-(3-Chlorophenyl)-4-methyl-1H-pyrazole-5-carboxamido)-3-phenylpropanamido)-1H-indole-2-carboxylic acid (**7q**): white solid product (60 mg, 21.5% yield), m.p.: 154–156 °C, decomposition. 1H -NMR: δ 13.48 (s, 1H), 11.66 (s, 1H), 10.06 (s, 1H), 7.98 (s, 1H), 7.96–7.91 (m, 1H), 7.60 (s, 1H), 7.52 (s, 1H), 7.38–7.14 (m, 9H), 7.03 (s, 1H), 4.93–4.87 (m, 1H), 3.19–3.16 (m, 2H), 2.31 (s, 3H). ESI-MS (m/z) = 541.99 $[M + H]^+$, HRMS(ESI) calcd. For $C_{29}H_{25}ClN_5O_4^+$: $[M + H]^+ m/z$: 542.1590, found: 542.1577.

(*S*)-5-(2-(3-(3-Chlorophenyl)-1,4-dimethyl-1H-pyrazole-5-carboxamido)-3-phenylpropanamido)-1H-indole-2-carboxylic acid (**7r**): white solid product (59 mg, 20.9% yield), m.p.: 148–150 °C, decomposition. 1H -NMR: δ 12.86 (s, 1H), 11.66 (s, 1H), 10.05 (s, 1H), 7.94 (s, 1H), 7.85–7.83 (d, J = 8.4 Hz, 1H), 7.56–7.53 (m, 3H), 7.40–7.24 (m, 6H), 7.20–7.18 (m, 1H), 7.03 (s, 1H), 4.94–4.89 (m, 1H), 3.75 (s, 3H), 3.18–3.10 (m, 2H), 2.09 (s, 3H). HRMS(ESI) calcd. For $C_{30}H_{27}ClN_5O_4^+$: $[M + H]^+ m/z$: 556.1746, found: 556.1735.

(*S*)-5-(2-(3-(3-Chloro-2-fluorophenyl)-1H-pyrazole-5-carboxamido)-3-(4-fluorophenyl)propanamido)-1H-indole-2-carboxylic acid (**7s**): white solid product (151 mg, 54.3% yield), m.p.: 186–188 °C, decomposition. 1H -NMR: δ 13.87 (s, 1H), 12.99–12.88 (m, 1H), 11.64 (s, 1H), 10.15 (s, 1H), 8.99–8.91 (m, 1H), 7.97 (s, 1H), 7.94 (s, 1H), 7.58 (s, 1H), 7.39–7.29 (m, 5H), 7.15–7.02 (m, 2H), 6.96 (s, 1H), 4.90–4.85 (m, 1H), 3.30–3.09 (m, 2H). ^{13}C -NMR: δ 169.64, 163.18, 162.37, 159.96, 155.40, 152.91, 134.32, 134.16, 131.74, 131.32, 131.24, 130.08, 129.90, 126.99, 126.91, 125.79, 120.96, 118.76, 115.04, 114.83, 112.63, 112.26, 107.16, 106.21, 55.32, 36.93. ESI-MS (m/z) = 563.82 $[M + H]^+$, HRMS(ESI) calcd. For $C_{28}H_{21}ClF_2N_5O_4^+$: $[M + H]^+ m/z$: 564.1245, found: 564.1234.

(*S*)-5-(2-(3-(3-Chloro-2-fluorophenyl)-1H-pyrazole-5-carboxamido)-3-(3-fluorophenyl)propanamido)-1H-indole-2-carboxylic acid (**7t**): white solid product (154 mg, 55.7% yield), m.p.: 174–176 °C, decomposition. 1H -NMR: δ 13.92–13.75 (m, 1H), 13.03–12.81 (m, 1H), 11.66 (s, 1H), 10.12 (s, 1H), 7.97 (s, 1H), 7.87 (s, 1H), 7.59–7.56 (m, 1H), 7.54–7.27 (m, 5H), 7.21–6.93 (m, 4H), 4.94–4.88 (m, 1H), 3.29–3.13 (m, 2H). ESI-MS (m/z) = 563.84 $[M + H]^+$, HRMS(ESI) calcd. For $C_{28}H_{21}ClF_2N_5O_4^+$: $[M + H]^+ m/z$: 564.1245, found: 564.1234.

(*S*)-5-(2-(3-(3-Chloro-2-fluorophenyl)-1H-pyrazole-5-carboxamido)-3-(pyridin-4-yl)propanamido)-1H-indole-2-carboxylic acid (**7u**): grey solid product (92 mg, 32.7% yield), m.p.: 199–201 °C, decomposition. 1H -NMR: δ 13.87 (s, 1H), 12.83 (s, 1H), 11.69 (s, 1H), 8.96 (s, 1H), 8.50 (s, 1H), 7.98 (s, 1H), 7.93 (s, 1H), 7.69–7.39 (m, 6H), 7.05 (s, 1H), 5.00–4.95 (m, 1H), 3.27–3.17 (m, 2H). ESI-MS (m/z) = 547.01 $[M + H]^+$, HRMS(ESI) calcd. For $C_{27}H_{21}ClFN_6O_4^+$: $[M + H]^+ m/z$: 547.1291, found: 547.1279.

(*S*)-5-(2-(3-(3-Chloro-2-fluorophenyl)-1H-pyrazole-5-carboxamido)-3-(pyridin-3-yl)propanamido)-1H-indole-2-carboxylic acid (**7v**): grey solid product (240 mg, 85.3% yield), m.p.: 175–177 °C, decomposition. 1H -NMR: δ 13.86 (s, 1H), 12.88 (s, 1H), 11.69 (s, 1H), 10.15 (s, 1H), 8.99 (s, 1H), 8.57 (s, 1H), 8.41–8.40 (d, J = 4.4 Hz, 1H), 7.98 (s, 1H), 7.88 (s, 1H), 7.81–7.80 (d, J = 6.8 Hz, 1H), 7.52 (s, 1H),

7.39–7.10 (m, 4H), 7.04 (s, 1H), 4.95–4.89 (m, 1H), 3.25–3.14 (m, 2H). ESI-MS (m/z) = 547.05 $[M + H]^+$, HRMS(ESI) calcd. For $C_{27}H_{21}ClFN_6O_4$: $[M + H]^+$ m/z : 547.1291, found: 547.1272.

(*S*)-5-(2-(3-(3-Chloro-2-fluorophenyl)-1H-pyrazole-5-carboxamido)-3-(pyridin-2-yl)propanamido)-1H-indole-2-carboxylic acid (**7w**): white solid product (109 mg, 38.7% yield), m.p.: 192–194 °C, decomposition. 1H -NMR: δ 11.68 (s, 1H), 10.19 (s, 1H), 8.71–8.70 (d, J = 4.4 Hz, 1H), 8.12 (s, 1H), 7.97 (s, 1H), 7.89–7.86 (m, 1H), 7.71–7.70 (d, J = 6.0 Hz, 1H), 7.61–7.57 (t, J = 6.8 Hz, 2H), 7.36–7.30 (m, 4H), 7.03 (s, 1H), 5.13–5.11 (m, 1H), 3.56–3.39 (m, 2H). ESI-MS (m/z) = 547.04 $[M + H]^+$, HRMS(ESI) calcd. For $C_{27}H_{21}ClFN_6O_4$: $[M + H]^+$ m/z : 547.1291, found: 547.1275.

(*S*)-Ethyl 5-(4-(*tert*-butoxy)-2-((*tert*-butoxycarbonyl)amino)-4-oxobutanamido)-1H-indole-2-carboxylate (**17**): To a mixture of ethyl 5-amino-1H-indole-2-carboxylate (2.00 g, 9.8 mmol), pyridine (3.00 g, 19.6 mmol) and (*S*)-4-(*tert*-butoxy)-2-((*tert*-butoxycarbonyl)amino)-4-oxobutanoic acid (**16**, 2.83g, 9.8 mmol) in CH_2Cl_2 (30 mL) was added $POCl_3$ (1.16 g, 14.7 mmol) at -10 °C dropwise. After addition, the reaction mixture was stirred at -10 °C for 1 h when TLC analysis indicated completion of reaction. The mixture was washed by hydrochloric acid (1 M, 10 mL), dried by Na_2SO_4 and filtered. The filtrate was evaporated in vacuum and the residue was purified on column chromatography (*n*-hexane:ethyl acetate = 50:1 to 2:1) to get **17** as a white solid (1.77 g, 36.7% yield), m.p.: 119–121 °C, decomposition. 1H -NMR: δ 11.78 (s, 1H), 9.83 (s, 1H), 7.98 (s, 1H), 7.36 (s, 2H), 7.09–7.08 (m, 1H), 4.45–4.44 (m, 1H), 4.35–4.29 (m, 2H), 2.69–2.65 (m, 1H), 2.52–2.46 (m, 1H), 1.46–1.30 (m, 21H). ESI-MS (m/z) = 475.90 $[M + H]^+$, HRMS(ESI) calcd. For $C_{24}H_{33}KN_3O_7$: $[M + K]^+$ m/z : 514.1950, found: 514.1947.

(*S*)-3-((*tert*-Butoxycarbonyl)amino)-4-((2-(ethoxycarbonyl)-1H-indol-5-yl)amino)-4-oxobutanoic acid (**18**): To a mixture of **17** (1.7 g, 3.6 mmol) in THF (5 mL) was added TFA (5 mL) at 0 °C. After addition, the mixture was stirred at room temperature for 6 h when TLC analysis indicated completion of reaction. The reaction mixture was evaporated in vacuum, then to the residue was added THF (20 mL), H_2O (10 mL), Et_3N (3.6 g, 36 mmol) and (Boc) $_2O$ (772 mg, 3.6 mmol) and the reaction was stirred at room temperature overnight. TLC analysis showed the reaction was complete and the reaction mixture was evaporated in vacuum. To the residue was added H_2O (10 mL), extracted by MTBE (3 mL) and acidified by hydrochloric acid (1 M) to pH = 5. The aqueous layer was extracted by ethyl acetate for 3 times (10 mL \times 3), and the combined organic layer was dried by Na_2SO_4 , filtered and concentrated in vacuum to afford **18** as a grey solid (543 mg, 35.8% yield), m.p.: 123–125 °C, decomposition. 1H -NMR: δ 11.97 (s, 1H), 11.77 (s, 1H), 9.90 (s, 1H), 7.98 (s, 1H), 7.35 (s, 2H), 7.10–7.08 (m, 1H), 4.42–4.40 (m, 1H), 4.34–4.29 (m, 2H), 2.68–2.63 (m, 1H), 2.56–2.52 (m, 1H), 1.38–1.30 (m, 12H). ESI-MS (m/z) = 419.82 $[M + H]^+$, HRMS(ESI) calcd. For $C_{20}H_{25}KN_3O_7$: $[M + K]^+$ m/z : 458.1324, found: 458.1322.

(*S*)-Ethyl

5-(4-(4-acetylpiperazin-1-yl)-2-((*tert*-butoxycarbonyl)amino)-4-oxobutanamido)-1H-indole-2-carboxylate (**19a**): To a mixture of **18** (200 mg, 0.48 mmol) in DMF (4 mL) was added 1-(piperazin-1-yl)ethanone (61 mg, 0.48 mmol), *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride (183 mg, 0.96 mmol), 1-hydroxybenzotriazole (129 mg, 0.96 mmol) and *N,N*-diisopropylethylamine (185 mg, 1.43 mmol). After addition, the reaction mixture was stirred at room temperature for 6 h when TLC analysis indicated completion of reaction. Then H_2O (40 mL) was added and the mixture was extracted by ethyl acetate (15 mL \times 3) for 3 times. The combined organic layer was dried, filtered and the filtrate was concentrated in vacuum to get **19a** as a brown solid (176.3 mg, 69.8% yield). 1H -NMR: δ 11.76 (s, 1H), 9.81 (s, 1H), 7.94 (s, 1H), 7.36 (s, 1H), 7.09–7.07 (d, J = 2.0 Hz, 1H), 6.98–6.96 (d, J = 8.0 Hz, 1H), 4.50–4.48 (m, 1H), 4.34–4.29 (m, 2H), 3.45–3.39 (m, 8H), 2.75–2.72 (m, 2H), 1.99 (s, 3H), 1.37–1.30 (m, 12H). ESI-MS (m/z) = 529.95 $[M + H]^+$.

(*S*)-Ethyl 5-(2-((*tert*-butoxycarbonyl)amino)-4-morpholino-4-oxobutanamido)-1H-indole-2-carboxylate (**19b**): Compounds **19b** were synthesized from **18** and morpholine according to the procedure described for the preparation of **19a**. Grey solid product (137.2 mg, 58.9% yield), m.p.: 144–146 °C,

decomposition. $^1\text{H-NMR}$: δ 11.76 (s, 1H), 9.81 (s, 1H), 8.00 (s, 1H), 7.36 (s, 2H), 7.08 (s, 1H), 6.96–6.94 (d, $J = 7.2$ Hz, 1H), 4.49–4.48 (m, 1H), 4.34–4.29 (qd, $J = 7.2$, 2H), 3.54–3.41 (m, 8H), 2.72 (m, 2H), 1.38–1.30 (m, 12H). ESI-MS (m/z) = 488.97 $[\text{M} + \text{H}]^+$, HRMS(ESI) calcd. For $\text{C}_{24}\text{H}_{32}\text{KN}_4\text{O}_7^+$: $[\text{M} + \text{K}]^+ m/z$: 527.1903, found: 527.1894.

(S)-Ethyl

5-(4-(4-acetylpiperazin-1-yl)-2-(5-(3-chloro-2-fluorophenyl)-1H-pyrazole-3-carboxamido)-4-oxobutanamido)-1H-indole-2-carboxylate (**20a**): To a mixture of **19a** (170 mg, 0.32 mmol) in ethyl acetate (1 mL) was added hydrochloric/ethyl acetate (10 mL, saturated solution) and the reaction mixture was stirred at room temperature overnight. Then TLC analysis showed reaction was complete and the suspension was filtered to afford the intermediate. To the intermediate (150 mg, 0.32 mmol) in DMF (3 mL) was added **11f** (78 mg, 0.32 mmol), *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride (124 mg, 0.64 mmol), 1-hydroxybenzotriazole (87 mg, 0.64 mmol), and *N,N*-diisopropylethylamine (124 mg, 0.96 mmol) and the reaction mixture was stirred at room temperature for 6 h when TLC analysis indicated completion of reaction. Then H_2O (30 mL) was added and the suspension was stirred for 10 min, filtered, dried at 50 °C for 4 h to get **20a** as a brown solid (91.2 mg, 43.3% yield), m.p.: 156–158 °C, decomposition. $^1\text{H-NMR}$: δ 13.94 (m, 1H), 11.78 (s, 1H), 10.04–9.91 (m, 1H), 8.80–8.78 (m, 1H), 8.01 (s, 1H), 7.94–7.82 (m, 1H), 7.62–7.54 (m, 1H), 7.44–7.11 (m, 4H), 7.08 (s, 1H), 5.00 (s, 1H), 4.36–4.29 (m, 2H), 3.58–3.39 (m, 8H), 2.93–2.88 (m, 2H), 1.97 (s, 3H), 1.34–1.30 (m, 3H). ESI-MS (m/z) = 651.97 $[\text{M} + \text{H}]^+$, HRMS(ESI) calcd. For $\text{C}_{31}\text{H}_{32}\text{ClFN}_7\text{O}_6^+$: $[\text{M} + \text{H}]^+ m/z$: 652.2081, found: 652.2070.

(S)-Ethyl

5-(2-(5-(3-chloro-2-fluorophenyl)-1H-pyrazole-3-carboxamido)-4-morpholino-4-oxobutanamido)-1H-indole-2-carboxylate (**20b**): Compounds **20b** were synthesized from **19b** and **11f** according to the procedure described for the preparation of **20a**. Grey solid product (90.3 mg, 52.2 % yield), m.p.: 136–138 °C, decomposition. $^1\text{H-NMR}$: δ 13.90 (s, 1H), 11.78 (s, 1H), 9.98 (s, 1H), 8.01 (s, 1H), 7.88 (s, 1H), 7.60–7.53 (m, 2H), 7.41–7.30 (m, 4H), 7.08 (s, 1H), 5.03–4.97 (m, 1H), 4.38–4.29 (m, 2H), 3.63–3.38 (m, 8H), 2.93–2.80 (m, 2H), 1.38–1.30 (m, 3H). ESI-MS (m/z) = 610.95 $[\text{M} + \text{H}]^+$, HRMS(ESI) calcd. For $\text{C}_{29}\text{H}_{29}\text{ClFN}_6\text{O}_6^+$: $[\text{M} + \text{H}]^+ m/z$: 611.1806, found: 611.1811.

(S)-5-(4-(4-Acetylpiperazin-1-yl)-2-(5-(3-chloro-2-fluorophenyl)-1H-pyrazole-3-carboxamido)-4-oxobutanamido)-1H-indole-2-carboxylic acid (**7x**): To a mixture of **20a** (85 mg, 0.13 mmol) in EtOH (4 mL) and H_2O (2 mL) was added LiOH· H_2O (40 mg, 0.95) and the reaction mixture was stirred at room temperature for 5 h when TLC analysis indicated completion of reaction. The mixture was evaporated on a rotary evaporator in vacuum, then the residue was acidified by hydrochloric acid (1 M) to pH 3–4 and filtered. The filter cake was dried at 50 °C for 4 h to get **7x** as a white solid (62 mg, 76.4% yield), m.p.: 101–103 °C, decomposition. $^1\text{H-NMR}$ (400 MHz, DMSO- d_6): δ 13.94 (s, 1H), 11.63 (s, 1H), 10.00 (s, 1H), 7.98 (s, 1H), 7.89 (s, 1H), 7.58 (s, 1H), 7.43–7.32 (m, 4H), 7.01 (s, 1H), 5.01–5.00 (m, 1H), 3.57–3.47 (m, 6H), 2.95–2.85 (m, 4H), 2.00 (s, 3H). ESI-MS (m/z) = 623.94 $[\text{M} + \text{H}]^+$, HRMS (ESI) calcd. For $\text{C}_{29}\text{H}_{28}\text{ClFN}_7\text{O}_6^+$: $[\text{M} + \text{H}]^+ m/z$: 624.1768, found: 624.1755.

(S)-5-(2-(3-(3-Chloro-2-fluorophenyl)-1H-pyrazole-5-carboxamido)-4-morpholino-4-oxobutanamido)-1H-indole-2-carboxylic acid (**7y**): Compounds **7y** were synthesized from **20b** according to the procedure described for the preparation of **7x**. White solid product (59 mg, 77.8% yield), m.p.: 175–177 °C, decomposition. $^1\text{H-NMR}$: δ 13.95–13.84 (m, 1H), 11.62–11.60 (m, 1H), 10.01–9.98 (m, 1H), 8.81 (s, 1H), 8.38–8.36 (m, 1H), 7.98 (s, 1H), 7.90–7.82 (m, 1H), 7.58 (s, 1H), 7.48–7.28 (m, 3H), 7.00 (s, 1H), 5.01–4.92 (m, 1H), 3.57–3.42 (m, 4H), 3.39–3.29 (m, 4H), 2.96–2.92 (m, 2H). ESI-MS (m/z) = 582.96 $[\text{M} + \text{H}]^+$, HRMS(ESI) calcd. For $\text{C}_{27}\text{H}_{26}\text{ClFN}_6\text{O}_6^+$: $[\text{M} + \text{H}]^+ m/z$: 583.1503, found: 583.1485.

(S)-2-(5-(3-Chloro-2-fluorophenyl)-1H-pyrazole-3-carboxamido)-3-(4-nitrophenyl)propanoic acid (**22**): A mixture of 3-(3-chloro-2-fluorophenyl)-1H-pyrazole-5-carboxylic acid (**11f**, 2.2 g, 8.43 mmol), (S)-methyl 2-amino-3-(4-nitrophenyl)propanoate (**21**, 2.0 g, 8.43 mmol), 1-hydroxybenzotriazole (2.3 g, 17.04 mmol), *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride (3.2 g, 17.04 mmol)

and *N,N*-diisopropylethylamine (3.2 g, 24.80 mmol) in DMF (20 mL) was stirred at room temperature overnight. Then TLC analysis showed reaction was complete and H₂O (200 mL) was added, then the suspension was stirred for 0.5 h and filtered. The filter cake was transferred to a round-bottomed flask, and MeOH (60 mL), H₂O (30 mL) and LiOH·H₂O (1.0 g, 23.8 mmol) was added. The reaction mixture was stirred at room temperature for 2 h when TLC analysis indicated completion of reaction, evaporated on a rotary evaporator in vacuum, then H₂O (50 mL) was added, acidified by hydrochloric acid (1 M) to pH 3–4 and filtered. The filter cake was dried at 50 °C for 8 h to afford **22** as a yellow solid (3.25 g, 89.0% yield), m.p.: 167–169 °C, decomposition. ¹H-NMR: δ 14.01–13.79 (m, 1H), 8.11–8.02 (m, 2H), 7.87–7.84 (m, 1H), 7.59–7.56 (m, 1H), 7.49–7.42 (m, 2H), 7.36–7.22 (m, 1H), 7.06 (s, 1H), 4.42–4.29 (m, 1H), 3.32–3.19 (m, 2H). ESI-MS (*m/z*) = 432.94 [M + H]⁺, HRMS(ESI) calcd. For C₁₉H₁₅ClFN₄O₅⁺: [M + H]⁺ *m/z*: 433.0710, found: 433.0708.

(*S*)-Ethyl

5-(3-(4-aminophenyl)-2-(5-(3-chloro-2-fluorophenyl)-1H-pyrazole-3-carboxamido)propanamido)-1H-indole-2-carboxylate (**23**): A mixture of compound **22** (3.00 g, 6.93 mmol), ethyl 5-amino-1H-indole-2-carboxylate (1.42 g), *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride (2.66 g, 13.9 mmol), 1-hydroxybenzotriazole (1.87 g, 13.9 mmol) and *N,N*-diisopropylethylamine (1.79 g, 13.9 mmol) in DMF (20 mL) was stirred at room temperature overnight when TLC analysis indicated completion of reaction, then H₂O (200 mL) was added. The suspension was stirred for 10 min and filtered. The filter cake was dried at room temperature overnight and resolved in MeOH (200 mL) and ethyl acetate (100 mL). To the solution was added Pd/C (10%, 0.30 g) and the reaction mixture was stirred at the atmosphere of H₂ overnight when TLC analysis indicated completion of reaction. The suspension was filtered and the filtrate was concentrated in vacuum to afford intermediate **23** as a grey solid (3.1 g, 75.6% yield), m.p.: 120–122 °C, decomposition. ¹H-NMR: δ 13.77 (s, 1H), 11.80 (s, 1H), 10.20 (s, 1H), 8.99–8.69 (m, 2H), 7.99 (s, 1H), 7.91 (s, 1H), 7.38–6.98 (m, 7H), 6.91 (s, 1H), 6.81–6.80 (d, *J* = 2.4 Hz, 2H), 4.88–4.86 (m, 1H), 4.34–4.29 (qd, *J* = 6.8 Hz, 2H), 3.17–3.10 (m, 2H), 1.34–1.31 (m, 3H). ¹³C-NMR: δ 170.51, 161.92, 147.33, 135.04, 132.57, 130.40, 128.58, 127.48, 127.26, 126.30, 125.51, 119.84, 114.71, 113.25, 112.79, 108.33, 106.65, 61.05, 54.03, 40.76, 14.94. ESI-MS (*m/z*) = 588.98 [M + H]⁺, HRMS(ESI) calcd. For C₃₀H₂₇ClFN₆O₄⁺: [M + H]⁺ *m/z*: 589.1688, found: 589.1755.

(*S*)-5-(3-(4-Aminophenyl)-2-(5-(3-chloro-2-fluorophenyl)-1H-pyrazole-3-carboxamido)propanamido)-1H-indole-2-carboxylic acid (**7z**): To a mixture of compound **23** (140 mg, 0.24 mmol) in MeOH (4 mL) and H₂O (2 mL) was added LiOH·H₂O (52 mg, 1.20 mmol) and the mixture was stirred at 40 °C for 4 h when TLC analysis indicated completion of reaction. The mixture was concentrated and H₂O (2 mL) was added. The solution was acidified with hydrochloric acid (1 M) to pH=5, filtered and the filter cake was washed by H₂O (2 mL), dried at 50 °C for 3 h to afford **7z** as a brown solid (98.0 mg, 72.8% yield), m.p.: 209–211 °C, decomposition. ¹H-NMR: δ 13.88–13.86 (m, 1H), 11.64 (s, 1H), 10.10–10.04 (m, 1H), 8.82 (s, 1H), 7.96 (s, 1H), 7.89 (s, 1H), 7.58 (s, 1H), 7.57–7.29 (m, 6H), 7.22–6.98 (m, 3H), 6.45–6.43 (d, *J* = 8.0 Hz, 2H), 4.80–4.74 (m, 1H), 3.02–2.92 (m, 2H). ESI-MS (*m/z*) = 560.92 [M + H]⁺, HRMS(ESI) calcd. For C₂₈H₂₃ClFN₆O₄⁺: [M + H]⁺ *m/z*: 561.1448, found: 561.1439.

Ethyl

5-((2*S*)-2-(5-(3-chloro-2-fluorophenyl)-1H-pyrazole-3-carboxamido)-3-(4-(2-methylcyclopropane-carboxamido)phenyl)propanamido)-1H-indole-2-carboxylate (**24za**): To a mixture of compound **23** (200 mg, 0.34 mmol), 2-methylcyclopropanecarboxylic acid (34 mg, 0.34 mmol) and pyridine (54 mg, 0.68 mmol) in CH₂Cl₂ (5 mL) was added POCl₃ (78 mg, 0.51 mmol) at −10 °C dropwise. After addition, the reaction mixture was stirred at −10 °C for 1 h when TLC analysis indicated completion of reaction. The mixture was added H₂O (0.5 mL), concentrated in vacuum, and the residue was purified by Prep-TLC to afford desired product **24za** as a brown solid (76 mg, 33.3% yield), m.p.: 227–229 °C, decomposition. ¹H-NMR: δ 13.85 (s, 1H), 11.80 (s, 1H), 10.10 (s, 1H), 9.99 (s, 1H), 7.98 (s, 1H), 7.91 (s, 1H), 7.57 (s, 1H), 7.48–7.10 (m, 9H), 7.05 (s, 1H), 4.86–4.85 (m, 1H), 4.35–4.29 (qd, *J* = 6.8 Hz, 2H), 3.12–3.02 (m, 2H), 1.46–1.45 (m, 1H), 1.34–1.31 (m, 3H), 1.22–1.16 (m, 1H), 1.08–1.05 (m, 3H),

0.96–0.94(m, 1H), 0.58(s, 1H). ESI-MS (m/z) = 670.92 $[M + H]^+$, HRMS(ESI) calcd. For $C_{35}H_{33}ClFN_6O_5^+$: $[M + H]^+$ m/z : 671.2180, found: 671.2178.

5-((2*S*)-2-(5-(3-Chloro-2-fluorophenyl)-1*H*-pyrazole-3-carboxamido)-3-(4-(2-methylcyclopropane-carboxamido)phenyl)propanamido)-1*H*-indole-2-carboxylic acid (**7za**): Compounds **7za** was synthesized from compound **24za** according to the procedure described for the preparation of **7z**. Grey solid product (45 mg, 63.7% yield), m.p.: 212–214 °C, decomposition. 1H -NMR: δ 13.85 (s, 1H), 12.83 (s, 1H), 11.67 (s, 1H), 10.12 (s, 1H), 8.12 (s, 1H), 7.98 (s, 1H), 7.60–7.57 (m, 1H), 7.52–7.04 (m, 6H), 7.03 (s, 1H), 4.88–4.70 (m, 1H), 3.14–3.01 (m, 2H), 1.48–1.44 (m, 1H), 1.21–1.17(m, 1H), 1.16–1.08 (m, 3H), 1.06–1.04 (m, 1H), 0.56–0.59 (m, 1H). ^{13}C -NMR: δ 171.23, 169.68, 162.96, 155.35, 152.85, 138.12, 137.95, 134.30, 132.17, 131.71, 130.05, 129.56, 126.92, 125.71, 120.90, 120.73, 118.80, 112.57, 112.21, 107.24, 106.11, 55.26, 37.26, 23.07, 17.61, 15.21, 11.90. ESI-MS (m/z) = 642.92 $[M + H]^+$, HRMS(ESI) calcd. For $C_{33}H_{29}ClFN_6O_5^+$: $[M + H]^+$ m/z : 643.1867, found: 643.1848.

(*S*)-Ethyl

5-(2-(5-(3-chloro-2-fluorophenyl)-1*H*-pyrazole-3-carboxamido)-3-(4-(4-methylpiperazine-1-carboxamido)phenyl)propanamido)-1*H*-indole-2-carboxylate (**24zb**): A mixture of compound **23** (300 mg, 0.51 mmol), pyridine (403 mg, 5.1 mmol), 4-methylpiperazine-1-carbonyl chloride hydrochloride (166 mg, 1.02 mmol), and 4-dimethylaminopyridine (13 mg, 0.10 mmol) in DMF (5 mL) was stirred at room temperature overnight when TLC analysis indicated completion of reaction. The mixture was added H₂O (40 mL) and extracted by ethyl acetate for 3 times (15 mL \times 3). The combined organic layer was dried and concentrated in vacuum to get intermediate **24zb** (223 mg, 60.8% yield), m.p.: 174–176 °C, decomposition. 1H -NMR: δ 13.86 (s, 1H), 11.80 (s, 1H), 10.14 (s, 1H), 8.44 (s, 1H), 7.99–7.89 (m, 2H), 7.58 (s, 1H), 7.49–7.34 (m, 6H), 7.32–7.21 (m, 2H), 7.09 (s, 1H), 4.86–4.84 (m, 1H), 4.34–4.29 (qd, J = 7.2 Hz, 2H), 3.60–3.04 (m, 10H), 2.29 (s, 3H), 1.34–1.31 (m, 3H). ESI-MS (m/z) = 715.22 $[M + H]^+$, HRMS(ESI) calcd. For $C_{36}H_{37}ClFN_8O_5^+$: $[M + H]^+$ m/z : 715.2554, found: 715.2543.

(*S*)-5-(2-(5-(3-Chloro-2-fluorophenyl)-1*H*-pyrazole-3-carboxamido)-3-(4-(4-methylpiperazine-1-carboxamido)phenyl)propanamido)-1*H*-indole-2-carboxylic acid (**7zb**): Compound **7zb** was synthesized from compound **24zb** according to the procedure described for the preparation of **7z**. Grey solid product (153 mg, 73.4% yield), m.p.: 203–205 °C, decomposition. 1H -NMR: δ 13.88 (s, 1H), 11.66 (s, 1H), 10.10 (s, 1H), 8.44 (s, 1H), 7.97 (s, 1H), 7.88 (s, 1H), 7.58 (s, 1H), 7.38–7.20 (m, 9H), 7.03 (s, 1H), 4.86–4.85 (m, 1H), 3.48–3.44 (m, 6H), 3.13–3.02 (m, 4H), 2.30 (3H, s). ESI-MS (m/z) = 687.11 $[M + H]^+$, HRMS(ESI) calcd. For $C_{34}H_{33}ClFN_8O_5^+$: $[M + H]^+$ m/z : 687.2241, found: 687.2222.

(*S*)-Ethyl

5-(2-(5-(3-chloro-2-fluorophenyl)-1*H*-pyrazole-3-carboxamido)-3-(4-(3-oxomorpholino)phenyl)-propanamido)-1*H*-indole-2-carboxylate (**24zc**): A mixture of 2-(2-chloroethoxy)acetic acid (48 mg, 0.34 mmol), compound **23** (200 mg, 0.34 mmol) and *N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (100 mg, 0.41 mmol) in THF (4 mL) was stirred at 60 °C for 4 h when TLC analysis indicated completion of reaction. The reaction mixture was concentrated in vacuum and THF (5 mL) was added to the residue. To the stirred mixture was added NaH (40 mg, 1 mmol) in portions at room temperature. After addition, the mixture was stirred at room temperature for 5 h and TLC showed reaction was complete. Then NH₄Cl solution (0.2 mL, concentrated solution) was added and the mixture was concentrated in vacuum. The residue was recrystallized from *n*-hexane and ethyl acetate to give **24zc** as a brown solid (174 mg, 76.0% yield). 1H -NMR: δ 11.84 (s, 1H), 10.45–10.39 (m, 1H), 8.47 (s, 3H), 8.02 (s, 2H), 7.41–7.39 (m, 3H), 7.28–7.26 (m, 3H), 7.23–7.19 (m, 2H), 4.90 (m, 1H), 4.34–4.28 (qd, J = 7.2 Hz, 2H), 3.92–3.89 (m, 2H), 3.68–3.59 (m, 2H), 3.40–3.38 (m, 2H), 3.17–3.07 (m, 2H), 1.33–1.30 (t, J = 7.2 Hz, 3H). ESI-MS (m/z) = 695.17 $[M + Na]^+$.

(*S*)-5-(2-(5-(3-Chloro-2-fluorophenyl)-1*H*-pyrazole-3-carboxamido)-3-(4-(3-oxomorpholino)phenyl)-propanamido)-1*H*-indole-2-carboxylic acid (**7zc**): Compounds **7zc** was synthesized from compound **24zc** according to the procedure described for the preparation of **7z**. Grey solid product (78.0 mg, 50.4%

yield), m.p.: 200–202 °C, decomposition. ¹H-NMR: δ 13.89 (s, 1H), 11.18 (s, 1H), 10.14 (s, 1H), 7.92–7.88 (m, 2H), 7.56–7.41 (m, 2H), 7.39–7.25 (m, 6H), 4.90–4.89 (m, 1H), 4.15 (s, 2H), 3.93–3.90 (m, 2H), 3.68–3.66 (m, 2H), 3.57–3.55 (m, 2H). ESI-MS (*m/z*) = 644.90 [M + H]⁺, HRMS (ESI) calcd. For C₃₂H₂₇ClFN₆O₆: [M + H]⁺ *m/z*: 645.1659, found: 645.1637.

3.3. Inhibition of FXIa In Vitro

The inhibition of FXIa in vitro was measured using human FXIa (Haematologic Technologies, Essex Junction, VT, USA) and Activated Protein C Chromogenic substrate BIOPHEN CS-21(66) (HYPHEN BioMed, NEUVILLE-SUR-OISE, France) in 96-well microtiter plates at 37 °C. The target compounds and compound **4** was dissolved, diluted in DMSO and analyzed at a final concentration range of 6.5 nM to 84.5 μM respectively. To the 96-well microtiter plates was added 15 μL test compound, 15 μL FXIa (37.5 pM) and 100 μL Tris buffer (adjust to pH 7.4 with hydrochloric acid containing 0.3 M NaCl and 50 mM Tris) in turn respectively. The negative control was composed of the same mixed solutions except replacing test compound with DMSO. The positive control was composed of the same mixed solutions except replacing test compound with compound **4**. After incubated for 5 min at 37 °C, Activated Protein C Chromogenic substrate (30 μL, 435 μM) was added and the mixture was incubated at 37 °C. The FXIa inhibitory activity was measured at 405 nm using a Spectra Max M5 (Molecular Devices, Sunnyvale, CA, USA). The IC₅₀ was calculated by IBM SPSS Statistics 22.0 (IBM Inc., North Castle, NY, USA) and the Probit function in it. IC₅₀ values were converted to Ki values by the following relationship:

$$K_i = IC_{50} / (1 + [S]/K_m)$$

3.4. aPTT In Vitro Coagulation Assays

A commercially available automatic Coagulation analyzer (Steellex Science Instrument Co., Ltd., Beijing, China) was employed to measure aPTT. The clotting times were also measured using the instrument itself, in accordance with the manufacturer's instructions. Increasing concentrations of inhibitor or solvent were added to rabbit (Beijing Longan Experimental Animal Breeding Center, SCXK(Jing)2016-0006, Beijing, China) plasma and incubated for 3 min at 37 °C. APTT was determined by automatic Coagulation analyzer.

3.5. Molecular Docking Method

The structure of FXIa receptor was taken from Protein Data Bank with the ID code 5E2O. The receptor was processed using Protein Preparation Wizard, which included solvent deletion, hydrogen addition, bond order assignment and disulfide treatment. The original ligand 5JM was used as the docking center to generate the receptor grid file with a box size of 15 Å. The designed compounds were prepared using LigPrep module, and Epik method was used to determine the possible ionization state at pH = 7.0 ± 2.0 with OPLS-2005 force field. Molecular docking calculations were carried out using Glide with default parameters at standard precision. All these calculations were performed in Schrödinger 2009 software (Glide version 5.5, Schrödinger, New York, NY, USA).

4. Conclusions

In summary, we defined 5-phenyl-1H-pyrazole-3-carboxylic acid derivatives as privileged fragments and assembled them into **7a–7zc** as pharmacophore for FXIa inhibitors. We synthesized and assessed the FXIa inhibitory potency of a series of 5-phenyl-1H-pyrazole-3-carboxamide derivatives. Finally, the SAR of them was systemically investigated to afford the lead compound **7za** (FXIa Ki = 90.37 nM, 1.5×aPTT in rabbit plasma = 43.33 μM) which exhibited good in vitro inhibitory potency against FXIa and excellent in vitro coagulation activity and lead optimization is ongoing in our lab. Furthermore, the binding mode of **7za** with FXIa was studied and the results suggest that the 2-methylcyclopropanecarboxamide group of **7za** forms two direct hydrogen bonds with Tyr58B and Thr35 in the FXIa backbone, making **7za** bind to FXIa in a highly efficient manner.

Author Contributions: Q.W. and Z.Z. conceived, designed and performed the synthetic experiment part; F.M. conceived, designed and performed the docking simulation study part; S.Z., X.Z. and J.Y. conceived, designed and performed the pharmacological test part; Q.W. wrote the paper; Y.X., C.H. assisted paper revision.

Funding: This research was funded by Tianjin Natural Science Foundation-Young Foundation (No. 17JCQNJC13700 and 17JCQNJC13100).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Raskob, G.E.; Angchaisuksiri, P.; Blanco, A.N.; Büller, H.; Gallus, A.; Hunt, B.J.; Hylek, E.M.; Kakkar, T.L.; Konstantinides, S.V.; McCumber, M. Thrombosis: A major contributor to global disease burden. *Semin. Thromb. Hemost.* **2014**, *40*, 724–735, doi:10.1055/s-0034-1390325.
2. Mahan, C.E.; Holdsworth, M.T.; Welch, S.M.; Borrego, M.; Spyropoulos, A.C. Deep-vein thrombosis: A United States cost model for a preventable and costly adverse event. *Thromb. Haemost.* **2011**, *106*, 405–415, doi:10.1160/TH11-02-0132.
3. Broussalis, E.; Anna, W.; Trinka, E.; Mutzenbach, S.; Killer, M. Latest developments in anticoagulant drug discovery. *Drug Discov. Today* **2014**, *19*, 921–935, doi:10.1016/j.drudis.2014.02.011.
4. Chen, Z.; Seiffert, D.; Hawes, B. Inhibition of factor XIa activity as a promising antithrombotic strategy. *Drug Discov. Today* **2014**, *19*, 1435–1439, doi:10.1016/j.drudis.2014.04.018.
5. Bane, C.E., Jr.; Gailani, D. Factor XI as a target for antithrombotic therapy. *Drug Discov. Today* **2014**, *19*, 1454–1458, doi:10.1016/j.drudis.2014.05.018.
6. Al-Horani, R.A.; Desai, U.R. Factor XIa inhibitors: A review of the patent literature. *Expert Opin. Ther. Pat.* **2016**, *26*, 323–345, doi:10.1517/13543776.2016.1154045.
7. Schumacher, W.A.; Luetzgen, J.M.; Quan, M.L.; Seiffert, D.A. Inhibition of factor XIa as a new approach to anticoagulation. *Arterioscler. Thromb. Vasc. Biol.* **2010**, *30*, 388–392, doi:10.1161/ATVBAHA.109.197178.
8. Löwenberg, E.C.; Meijers, J.C.; Monia, B.P.; Levi, M. Coagulation factor XI as a novel target for antithrombotic treatment. *J. Thromb. Haemost.* **2010**, *8*, 2349–2357, doi:10.1111/j.1538-7836.2010.04031.x.
9. Gailani, D.; Gruber, A. Factor XI as a Therapeutic Target. *Arterioscler. Thromb. Vasc. Biol.* **2016**, *36*, 1316–1322, doi:10.1161/ATVBAHA.116.306925.
10. Rosenthal, R.; Dreskin, O.; Rosenthal, N. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. *Proc. Soc. Exp. Biol. Med.* **1953**, *82*, 171–174.
11. Meijers, J.C.; Tekelenburg, W.L.; Bouma, B.N.; Bertina, R.M.; Rosendaal, F.R. High levels of coagulation factor XI as a risk factor for venous thrombosis. *N. Engl. J. Med.* **2000**, *342*, 696–701, doi:10.1056/NEJM200003093421004.
12. Salomon, O.; Steinberg, D.M.; Koren-Morag, N.; Tanne, D.; Seligsohn, U. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. *Blood* **2008**, *111*, 4113–4117, doi:10.1182/blood-2007-10-120139.
13. Büller, H.R.; Bethune, C.; Bhanot, S.; Gailani, D.; Monia, B.P.; Raskob, G.E.; Segers, A.; Verhamme, P.; Weitz, J.I. Factor XI antisense oligonucleotide for prevention of venous thrombosis. *N. Engl. J. Med.* **2015**, *372*, 232–240, doi:10.1056/NEJMoa1405760.
14. Perera, V.; Luetzgen, J.M.; Wang, Z.; Frost, C.E.; Yones, C.; Russo, C.; Lee, J.; Zhao, Y.; LaCreta, F.P.; Ma, X.; et al. First in human study to assess safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects. *Br. J. Clin. Pharmacol.* **2018**, *84*, 876–887, doi:10.1111/bcp.13520.
15. Pinto, D.J.P.; Orwat, M.J.; Smith, L.M., 2nd.; Quan, M.L.; Lam, P.Y.S.; Rossi, K.A.; Apedo, A.; Bozarth, J.M.; Wu, Y.; Zheng, J.J.; et al. Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212). *J. Med. Chem.* **2017**, *60*, 9703–9723, doi:10.1021/acs.jmedchem.7b01171.
16. Pinto, D.J.; Corte, J.R.; Gilligan, P.J.; Fang, T.; Smith, L.M., II; Wang, Y.; Yang, W.; Ewing, W.R. Novel Macrocycles as Factor XIa Inhibitors. WO2013022818A1 Patent, 14 July 2014.
17. Pinto, D.J.P.; Clark, C.G.; Smith, L.M., II; Orwat, M.J.; Jeon, Y.; Corte, J.R. Tetrahydroisoquinolines Containing Substituted Azoles as Factor XIa Inhibitors. WO2014160668A1 Patent, 2 October 2014.
18. Smith, L.M., 2nd.; Orwat, M.J.; Hu, Z.; Han, W.; Wang, C.; Rossi, K.A.; Gilligan, P.J.; Pabbisetty, K.B.; Osuna, H.; Corte, J.R.; et al. Novel phenylalanine derived diamides as Factor XIa inhibitors. *Bioorg. Med. Chem. Lett.* **2016**, *26*, 472–478, doi:10.1016/j.bmcl.2015.11.089.

19. Hangeland, J.J.; Friends, T.J.; Rossi, K.A.; Smallheer, J.M.; Wang, C.; Sun, Z.; Corte, J.R.; Fang, T.; Wong, P.C.; Rendina, A.R.; et al. Phenylimidazoles as Potent and Selective Inhibitors of Coagulation Factor XIa with in Vivo Antithrombotic Activity. *J. Med. Chem.* **2014**, *57*, 9915–9932, doi:10.1021/jm5010607.
20. Rohrig, S.; Hillisch, A.; Strassburger, J.; Schmid, M.V.; Schlemmer, K.-H.; Tersteegen, A.; Buchmuller, A.; Gerdes, C.; Schaffer, M.; Kinzel, T.; et al. Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders. WO2014154794A1 Patent, 2 October 2014.
21. Fjellström, O.; Akkaya, S.; Beisel, H.G.; Eriksson, P.O.; Erixon, K.; Gustafsson, D.; Jurva, U.; Kang, D.; Karis, D.; Knecht, W.; et al. Creating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug design. *PLoS ONE* **2015**, *10*, e0113705, doi:10.1371/journal.pone.0113705.
22. Sidique, S.; Ardecky, R.; Su, Y.; Narisawa, S.; Brown, B.; Millán, J.L.; Sergienko, E.; Cosford, N.D. Design and synthesis of pyrazole derivatives as potent and selective inhibitors of tissue-nonspecific alkaline phosphatase (TNAP). *Bioorg. Med. Chem. Lett.* **2009**, *19*, 222–225, doi:10.1016/j.bmcl.2008.10.107.
23. Fleury, M.; Gendron, R.; Hughes, A.D. Neprilysin Inhibitors. U.S. Patent US20170020904A1 Patent, 26 January 2017.
24. Chae, E.; Shin, Y.J.; Ryu, E.J.; Ji, M.K.; Ryun Cho, N.; Lee, K.H.; Jeong, H.J.; Kim, S.J.; Choi, Y.; Seok, O.K.; et al. Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 2134–2139, doi:10.1016/j.bmcl.2013.01.116.
25. Pinto, D.J.; Smallheer, J.M.; Corte, J.R.; Austin, E.J.; Wang, C.; Fang, T.; Smith, L.M., 2nd.; Rossi, K.A.; Rendina, A.R.; Bozarth, J.M.; et al. Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties. *Bioorg. Med. Chem. Lett.* **2015**, *25*, 1635–1642, doi:10.1016/j.bmcl.2015.01.028.
26. Van Herk, T.; Brussee, J.; van den Nieuwendijk, A.M.; van der Klein, P.A.; IJzerman, A.P.; Stannek, C.; Burmeister, A.; Lorenzen, A. Pyrazole Derivatives as Partial Agonists for the Nicotinic Acid Receptor. *J. Med. Chem.* **2003**, *46*, 3945–3951, doi:10.1021/jm030888c.
27. Guido, G.; Cedric, G.; Roger, N.; Philippe, P. Pyrazole Derivatives. WO2012168260A1 Patent, 13 December 2012.
28. Gonzalez, R.J.; Vidal, J.B.; Gual, R.S. New Pyrazole Derivatives as CRAC Channel Modulators. EP2848615A1 Patent, 18 March 2015.
29. Nobuhisa, F.; Yohei, I.; Tetsuya, K.; Kuniko, S. Phenylalanine Derivative. JP2014227401A Patent, 8 December 2014.

Sample Availability: Samples of the compounds 7a–7zc are available from the authors.



© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).